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CHEMICAL SPACE EXPLORATION AROUND THIENO[3,2-d]PYRIMIDIN-
4(3H)-ONE SCAFFOLD LED TO A NOVEL CLASS OF HIGHLY ACTIVE 
CLOSTRIDIUM DIFFICILE INHIBITORS 
Xuwei Shao 
Clostridium difficile infection (CDI) is the leading cause of healthcare-associated 
infection in the United States. Therefore, development of novel treatments for CDI is a 
high priority. Toward this goal, we began in vitro screening of a structurally diverse in-
house library of 67 compounds against two pathogenic C. difficile strains (ATCC BAA 
1870 and ATCC 43255), which yielded a hit compound, 2-methyl-8-nitroquinazolin-
4(3H)-one (2) with moderate potency (MIC = 312/156 µM). Optimization of 2 gave 
lead compound 6a (2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one) with improved 
potency (MIC = 19/38 µM), selectivity over normal gut microflora, CC50s >606 µM 
against mammalian cell lines, and acceptable stability in simulated gastric and intestinal 
fluid. Further optimization of 6a at C2-, N3-, C4- and C7-positions resulted in a library 
of >50 compounds with MICs ranging from 3 – 800 µM against clinical isolates of C. 
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Chapter I. Introduction 
1.1. Clostridium difficile infection 
Clostridium difficile is a Gram-positive spore-forming anaerobic bacterium that causes 
diarrhea and serious intestinal conditions. Toxigenic strains of C. difficile produce two 
glycosylating toxins: toxin A (TcdA/enterotoxin) and toxin B (TcdB/cytotoxin), both 
of which initiate damage of the colon, life-threatening inflammation of the gut (C. 
difficile colitis), and a spectrum of intestinal pathologies ranging from mild diarrhea to 
pseudomembranous colitis in the infected host.1-3 The CDI, confined to the 
gastrointestinal tract, is usually triggered by the use of antibiotics, which disturbs the 
reproduction of normal and protective gut microflora allowing C. difficile to proliferate 
in the colon and to produce toxins.4 According to Centers for Disease Control and 
Prevention (CDC), about half a million cases of CDI occur each year in the US hospitals 
and long-term health care facilities with an estimation of 29,000 deaths. The prevalence 
and severity of CDI appear to be rising, partly due to a larger elder population with high 
risk factors, an increasing use of antibiotics, a higher proportion of hypervirulent 
bacterial isolates with increased production of lethal toxins A and B,5 and the emergence 
of hypervirulent epidemic strains (BI/Nap1/027).6  
1.2. Therapeutic options available for CDI 
However, therapeutic options available for CDI patients are limited. In 2010, the 
Infectious Diseases Society of America provided clinical practice guidelines for CDI, 
in which metronidazole, vancomycin and fidaxomicin are recommended.7 
Metronidazole diffuses into the organism, inhibits protein synthesis by interacting with 
DNA and causing a loss of helical DNA structure and strand breakage. Therefore, it 
causes cell death in susceptible organisms. 
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Figure 1. Products of metronidazole reduction. Modified based on previous report.8, 9 
Multiple steps are required for metronidazole molecules to perform their 
therapeutic function. After diffusing across the cell membranes of anaerobic and 
aerobic pathogens, nitro group on the molecules is reduced to form free radicals with 
cytotoxic effect (Figure 1). Hypoxic condition is required during the reduction, which 
explains the selectivity of metronidazole towards anaerobic C. difficile strains.10 The 
formed free radicals interact with various constituents in the cells, and lead to cell 
death.8  
Since approved by the US FDA, vancomycin has been an effective therapeutic option 
for CDI patients.11 In Gram-positive bacteria, vancomycin inhibits formation of polymer 
of glycopeptide (Figure 2). Because of the absence of peptide crosslink, peptidoglycan 
layer becomes less rigid and more permeable, and eventually the bacterium bursts from 
osmotic lysis.12  
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Figure 2. Mechanism of action of vancomycin. Modified based on previous report.13 
On the contrary to metronidazole or vancomycin, inhibitory activity of fidaxomicin 
against C. difficile strains is the result of blockage of RNA polymerase activity.14 To 
initialize transcription process, specific promoter σ combines with the core RNA 
polymerase (RNAP), which contains α-dimer, β-, β′-, and ω-subunits. Then the 
complex recognizes and binds to DNA template, which leads to the formation of open 
RNAP-DNA complex. One of the proposed mechanisms of action of fidaxomicin is 
that it binds to β′-subunit and σ factor, which blocks formation of the essential 
component (Figure 3).15 
 
Figure 3. Mechanism of action of fidaxomicin. Modified from previous report.13, 15 
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1.3. Drawbacks of medications used for CDI 
Currently available therapeutics (metronidazole, vancomycin and fidaxomicin) for CDI 
are inadequate in efficacy and/or tolerability.3 Both metronidazole and vancomycin 
treatments encounter substantial disease relapse.16 Metronidazole, an antibiotic with 
activity against a wide spectrum of anaerobic bacteria and parasites, is only 
recommended for the treatment of mild-to-moderate episodes and is inferior to 
vancomycin.17 Moreover, it is essentially 100% bioavailable leading to limiting 
concentrations in the colon, the prime location of CDI.18 Unlike metronidazole, 
vancomycin is minimally absorbed into the systemic circulation upon oral 
administration, thereby resulting in a high concentration in the colon.19 However, its 
broad spectrum of action against Gram-positive bacteria leads to a reduced microbiome 
diversity and the potential selection of vancomycin-resistant enterococci.20 In addition, 
recurrent infection caused by newer and stronger C. difficile strains is a formidable 
preclinical challenge.21 Both metronidazole and vancomycin treatments can worsen the 
condition of patients due to the loss of beneficial gut microbiota, and subsequent 
recurrence at an alarming rate. Selectively targeting C. difficile over normal gut flora 
has been considered as a strategy to achieve prevention of recurrence.22 Compared with 
vancomycin, fidaxomicin (a macrolide antibiotic) demonstrates a narrower spectrum of 
activity and selectivity towards C. difficile; however, it does not greatly improve 
sustained clinical responses especially against hypervirulent strains BI/NAP1/027.23 In 
view of the transient efficacy of these antibiotics, particularly of metronidazole and 
vancomycin, patients are predisposed to ~25% relapse rate as compared to 15% for 
fidaxomicin and a subsequent prolongation of C. difficile shedding and transmission.24, 
25 Although fidaxomicin treatment showed significantly lower rates of CDI recurrence 
compared to metronidazole and vancomycin, it does so only in non-NAP1 CDI patients. 
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In addition, clinical resistance to fidaxomicin has already been documented.24 Although 
93% of fidaxomicin remains unabsorbed after oral administration, it is detectable in the 
range of 25-50 ng/mL in the plasma of patients,26 which leads to a serious concern of 
potent cytotoxic effect. Moreover, the cost of fidaxomicin treatment is prohibitively 
expensive partly due to complexity in synthesizing a large molecule with molecular 
weight beyond 1000 Da. Although ridinilazole (NCT02784002) is currently 
undergoing clinical trials for the treatment of CDI, it remains to be seen whether it 
would offer any benefit over current treatment.27 Despite unmet medical need, progress 
toward anti-C. difficile drug development has been very limited.28-32 Therefore, the 
discovery of new “best-in-class” drugs to fight against C. difficile is needed to 
adequately address CDI.
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Chapter II. Design rationale 
To identify highly selective novel C. difficile inhibitors, we conducted whole-cell 
screening of a set of 67 in-house compounds (Table 1), comprising diverse structural 
classes (valine-, proline-, phenylalanine-, and tyrosine-derived thiazole 
peptidomimetics and quinazolinones, benzoxazines, indazoles, benzodioxines, 
imidazopyridines, and benzodioxepines) with molecular weights (MW) ranging from 
164 to 652 Da.  
Table 1. List of in-house compound library used for HTS 


















































































































































This screening method allowed us to ensure penetration of the C. difficile cell 
membrane as well as to obtain minimum inhibitory concentrations (MICs) as biological 
readouts to identify promising hit compounds. Each scaffold in the library had a 
sufficient number of structurally close analogues to produce robust results while 
capturing key SAR trends. This screening test identified two previously reported 
quinazolinone analogues33, 34 as hit compounds, 6-nitroquinazolin-4(3H)-one (1, MIC = 
	 16	
335/335 µM, hereafter, against two C. difficile clinical strains; ATCC BAA 1870/ATCC 
43255) and 2-methyl-8-nitroquinazolin-4(3H)-one (2, MIC = 312/156 µM) (3% 
success rate) that showed moderate to weak MICs. In vitro MIC values were compared 
with three FDA approved drugs, vancomycin, metronidazole and fidaxomicin. 
Compound 2 was established as a promising fragment hit for further medicinal 
chemistry optimization because of its selectivity profile toward multiple clinical strains 
of C. difficile over human normal microflora (MIC >1248 µM) such as Lactobacillus, 
Bifidobacterium, Escherichia coli, and Enterobacter cloacae) (Figure 4). Medicinal 
chemistry optimization of hit 2 via analogue synthesis produced compounds 3-5 with a 
loss of potency suggesting the contribution of the C8-nitro substituent. Next, we 
decided to implement scaffold hopping strategy, which led to identification of small 
MW scaffolds 6a (MIC = 19/38 µM), 6b (MIC = 41/41 µM) and 6c (MIC = 38/38 µM). 
Compound 6a was prioritized for further SAR study based on its structural novelty, 
ease of synthetic derivatization, favorable potency, selectivity, and in vitro mammalian 
cell toxicity as shown in Figure 4.  
 
Figure 4. Hit identification.  
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Chapter III. Experimental 
3.1. Chemicals and Bacterial Strains 
Chemical reagents and solvents were purchased from Aldrich Chemical Co. 
(Milwaukee, WI), AK scientific (Union City, CA), Combi-Blocks Inc. (San Diego, CA), 
TCI America (Portland, OR), Gold Biotechnology (St. Louis, MO), Alfa Aesar (Ward 
Hill, MA) and Sigma-Aldrich (St. Louis, MO), and were used as received. 
Table 2. Bacterial strains used in the study  





Clinical isolate from Main, USA. Toxinotype 





Clinical isolate from abdominal wound. 













Isolated from human mid-vaginal wall in March 
2010 in Richmond, Virginia.  
Bifidobacterium 
bifidum 212A 











Quality control strain 
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 Bacterial strains (Table 2) were purchased from American Type Culture Collection 
(ATCC) or Biodefense and Emerging Infections Research Resources Repository (BEI 
resources). Bacterial media were purchased from Becton, Dickinson and Company 
(Cockeysville, MD) while cell culture media and fetal bovine serum were purchased 
from Fisher scientific (Waltham, MA). 
3.2. Chemistry-General  
All chemicals reagents were confirmed for uniformity by thin layer chromatography 
(TLC) with silica gel as the adsorbent layer (250 microns) on aluminum backed plates 
(Agela Technologies, Torrance, CA). Reactions were monitored by TLC and visualized 
by ultraviolet (UV) light at 254 nm. 1H NMR spectra (at 400 MHz) and 13C NMR spectra 
(at 100 MHz) were recorded on a Bruker 400 UltrashieldTM spectrometer. Chemical 
shifts (δ) of 1H NMR and 13C NMR were reported downfield from tetramethylsilane 
(TMS, internal standard) in parts per million (ppm) units. The 1H NMR data are 
presented as follows: chemical shift [multiplicity s (singlet), bs (broad singlet), d 
(doublet), t (triplet), q (quartet), hept (heptet), dd (doublet of doublets), and m 
(multiplet), number of protons, coupling constant]. The 13C NMR (proton decoupled, 
fluorine coupled) data are presented as follows: chemical shift [multiplicity d (doublet)]. 
Flash chromatography was carried out on a Reveleris X2 flash chromatography system 
(Buchi Corporation, New Castle, DE). Preparative TLC was used for the purification 
of certain target compounds using Silica Gel GF 1000 μm 20x20 cm glass backed plates 
from Analtech (Miles Scientific, Newark, DE). Purity of the target compounds was 
established by HPLC analysis using Waters 600 HPLC system with a Waters 717 plus 
autosampler, Waters 2487 dual 18λ absorbance detector at 254 nm (Waters, Milford, 
MA) and a C18 reverse phase column (Luna® 5 µm C18 100 Å, LC Column 150 x 4.6 
mm) at respective flow rate. Purity of the target compounds was determined to be ≥ 95% 
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based on HPLC analysis. The purity of all target compounds was determined by the 
ratio of major peak area to the total combined area of peaks. Melting points were 
determined using Stuart digital melting point apparatus SMP20 (Cole-Parmer, 
Staffordshire, UK) and are uncorrected. Mass spectra were recorded for known target 
compounds using an Agilent 1260 infinity series liquid chromatography (LC) system 
(C18 column, Agilent InfinityLab poroshell 120, EC-C18, 2.7 μm 4.6 x 50 mm) 
connected with Agilent 6120 quadrupole mass spectrometer (MS). Aqueous solubility 
in PBS buffer and stability in simulated gastric fluid and simulated intestinal fluid were 
determined using Waters 600 HPLC system with a Waters 717 plus autosampler, 
Waters 2487 dual 19λ absorbance detector (Waters, Milford, MA) and a C18 reverse 
phase column (Symmetry C18, 5 μm, 3.9 x 150 mm) at a flow rate of 1 mL/min. The 
X-ray intensity data were measured on a Bruker APEX-II CCD system equipped with 
a graphite monochromator and a Mo sealed tube (λ = 0.71073 Å). High resolution mass 
spectra (HRMS) were obtained for all unknown target compounds from the Columbia 
University Chemistry Department Mass Spectrometry Facility on a Waters Xevo G2-
XS QToF mass spectrometer equipped with H-Class UPLC inlet and a LockSpray ESI 
source. 
3.3. Synthetic procedure 
3.3.1. General Procedure for Synthesis of Thienopyrimidinone Analogues 
(Method A).34 
Commercially available amino and methyl ester substituted aromatic/heteroaromatic 
compound (1 eq mmol) was added to a flask containing acetic anhydride (20 mL). After 
stirring at room temperature for 12 to 24 h, excess liquid was removed under vacuum. 
The crude product was then purified by flash chromatography with dry loading method 
as described below. The crude residue was dissolved in a mixture of acetone and 
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methanol (50:50) and 8 g of silica gel was added into the same flask. Completely dried 
solid was transferred into a solid loader and installed onto flash chromatography. 
Without further purification unless otherwise indicated, respective intermediates were 
stirred in 30% aqueous solution of ammonium hydroxide (30 mL) at rt until a complete 
conversion of starting material was observed by TLC. During the process, the mixture 
turned into a clear solution from a suspension. Ammonia was first released at a lower 
temperature under vacuum, and then water was evaporated at a higher temperature. A 
solid product was obtained by flash chromatography using dry loading method and 
dichloromethane/methanol as an eluent system. 
3.3.2. General Procedure for the Insertion of a Nitro Group on the Core 
Structures (Method B).35 
Concentrated sulfuric acid (10 mL) was cooled down to 0 °C on ice bath. Respective 
scaffold (1 eq) was added and stirred for half an hour before drop wise addition of 
fuming nitric acid (1 mL). The resulting mixture was stirred for half an hour at 0 °C 
and 8 h at rt to produce yellow solution, which was then poured into excess ice water 
and neutralized with NaHCO3 to pH 7. The solid precipitates were filtered and washed 
with water.36  
3.3.3. General Procedure for the Synthesis of C2-styryl Derivatives of 
Thienopyrimidinone Core (Method C).37, 38 
To a 0.5-2 mL microwave vial, compound 6a (1 eq), (un)substituted 
aromatic/heteroaromatic aldehydes (5 eq), and acetic acid (2 mL) were added. After the 
vial was crimped, the mixture was subjected to irradiation and the temperature was 
maintained at 180 °C for 1 h in a mono-cavity microwave initiator. After heating, 
compressed air was used to cool down the reaction mixture. The process was repeated 
	 21	
5 times and the resulting mixture was purified by flash chromatography using dry 
loading method and dichloromethane/methanol as an eluent system. 
3.3.4. General Procedure for Alkylation at N3-position of Thienopyrimidinone 
Core (Method D).39 
Compound 6a (1 eq) was reacted with (un)substituted phenylalkyl halide or halo acetate 
(1.8 eq) in the presence of K2CO3 (2 eq) in N,N-dimethylformamide (15 mL) at rt for 8-
12 h. After complete consumption of starting material monitored by TLC, the mixture 
was diluted with ethyl acetate (100 mL) and washed with saturated aqueous solution of 
NaHCO3 and brine three times each. Organic layer was dried over anhydrous MgSO4 
and evaporated under vacuum. The crude product was purified by flash 
chromatography using dry loading method and dichloromethane/methanol as an eluent 
system. 
3.3.5. 2-Methyl-8-nitroquinazolin-4(3H)-one (2).34 Intermediate 2-methyl-8-nitro-
4H-benzo[d][1,3]oxazin-4-one 17 (206 mg, 1.0 mmol) was used as starting material to 
prepare compound 2 according to method A as an orange solid (123 mg, 60% yield), 
mp 247-249 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.62 (s, 1H), 8.27 (dd, J = 
24.6 Hz, 7.4 Hz, 2H), 7.59 (t, J = 7.7 Hz, 1H), 2.37 (s, 3H). ESI-MS: m/z 206.1 [M + 
H]+. HPLC flow rate 0.5 mL/min, tR (acetonitrile/water 90:10) = 5.9 min, purity 99%. 
3.3.6. 2-Methylpyrido[2,3-d]pyrimidin-4(3H)-one (3).40 Intermediate 2-methyl-4H-
pyrido[2,3-d][1,3]oxazin-4-one 18 (162 mg, 1.0 mmol) was used as the starting 
material to synthesize target compound 3 according to method A as a white solid (78 
mg, 48% yield), mp 275-278 °C [lit. mp 261-263 °C].41 1H NMR (400 MHz; DMSO-d6; 
TMS) δ 12.50 (s, 1H), 8.90 (q, J = 5.2 Hz, 1H), 8.46 (dd, J = 12.0 Hz, 3.2 Hz, 1H), 7.48 
(q, J = 17.2 Hz, 1H), 2.40 (s, 3H). ESI-MS: m/z 162.1 [M + H]+. HPLC flow rate 0.5 
mL/min, tR (acetonitrile/water 90:10) = 4.2 min, purity 99%. 
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3.3.7. 8-Fluoro-2-methylquinazolin-4(3H)-one (4).34, 42 Intermediate 8-fluoro-2-
methyl-4H-benzo[d][1,3]oxazin-4-one 19 (179 mg, 1.0 mmol) was used for the 
preparation of 4 according to method A as a white solid (121 mg, 68% yield), mp 273-
275 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.45 (s, 1H), 7.94 (d, J = 7.9 Hz, 1H), 
7.73 – 7.68 (m, 1H,), 7.54 – 7.49 (m, 1H), 2.36 (s, 3H). ESI-MS: m/z 179.1 [M + H]+. 
HPLC flow rate 1 mL/min, tR (acetonitrile/water 65:35) = 5.7 min, purity 97%. 
3.3.8. 8-Amino-2-methylquinazolin-4(3H)-one (5).42 To a 50 mL beaker, compound 
2 (205 mg, 1.0 mmol), Pd/C (20 mg) and ethanol (20 mL) were added and the beaker 
was transferred into a Parr-hydrogenation vessel. Upon three times replacements of air 
by nitrogen, hydrogen gas was introduced until 50 psi. After no further consumption of 
hydrogen was observed, reaction mixture was removed and filtered through celite. 
Compound 5 was collected upon concentration under vacuum as a yellow solid (123 
mg, 70% yield), mp 232-234 °C [lit. mp 226-230 °C].34 1H NMR (400 MHz; DMSO-d6; 
TMS) δ 12.05 (s, 1H), 7.19 (dd, J = 7.7 Hz, 1.4 Hz, 1H), 7.11 (t, J = 15.3 Hz, 1H), 6.93 
(dd, J = 7.7 Hz, 1.2 Hz, 1H), 5.57 (s, 2H), 2.34 (s, 3H). ESI-MS: m/z 176.1 [M + H]+. 
HPLC flow rate 1 mL/min, tR (acetonitrile/water 65:35) = 4.9 min, purity 99%. 
3.3.9. 2-Methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one (6a). Nitro group was 
introduced onto 7a (166 mg, 1.0 mmol) according to method B to yield 6a as a white 
solid (158 mg, 75% yield), mp 249-252 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 
12.90 (s, 1H), 9.31 (s, 1H), 2.44 (s, 3H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 
159.23, 157.84, 149.26, 141.31, 138.99, 122.05, 21.87. HRMS (m/z): [M + H]+ calcd 
for C7H6N3O3S, 212.0124; found: 212.0099.  
3.3.10. 2-Methyl-7-nitrofuro[3,2-d]pyrimidin-4(3H)-one (6b). Compound 7b (150 
mg, 1.0 mmol) was subjected to nitration according to method B to obtain 6b as a white 
solid (160 mg, 82% yield), mp 270-273 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 
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12.98 (s, 1H), 8.05 (s, 1H), 2.39 (s, 3H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 
158.39, 154.56, 152.56, 147.18, 137.32, 108.19, 21.73. HRMS (m/z): [M + H]+ calcd 
for C7H6N3O4, 196.0353; found: 196.0333.  
3.3.11. 2-Methyl-7-nitrothieno[3,4-d]pyrimidin-4(3H)-one (6c). Nitration of 7c (166 
mg, 1.0 mmol) using method B gave 6c as a white solid (84 mg, 40% yield), mp 256-
258 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.43 (s, 1H), 8.84 (s, 1H), 2.39 (s, 
3H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 161.18, 157.40, 147.01, 138.43, 135.17, 
125.67, 22.41. HRMS (m/z): [M + H]+ calcd for C7H6N3O3S, 212.0124; found: 212.0131.  
3.3.12. 7-Nitrothieno[3,2-d]pyrimidin-4(3H)-one (6d).43 Compound 7d (152 mg, 1.0 
mmol) was nitrated as per method B to produce 6d as a white solid (130 mg, 69% yield), 
mp 240-243 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 13.03 (s, 1H), 9.35 (s, 1H), 
8.37 (s, 1H). ESI-MS: m/z 198.0 [M + H]+). HPLC flow rate 0.5 mL/min, tR 
(acetonitrile/water 90:10) = 5.8 min, purity 96%.  
3.3.13. 2-Ethyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one  (6e). Nitration of 7e (180 
mg, 1.0 mmol)) according to method B yielded 6e as a white solid (158 mg, 70% yield), 
mp 270-273 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.87 (s, 1H), 9.31 (s, 1H), 
2.70 (q, J = 5.7 Hz, 2H), 1.26 (t, J = 7.6 Hz, 3H). 13C NMR (100 MHz; DMSO-d6; TMS): 
δ 163.29, 157.96, 149.31, 141.51, 138.89, 122.25, 28.28, 11.93. HRMS (m/z): [M + H]+ 
calcd for C8H8N3O3S, 226.0281; found: 226.0289.  
3.3.14. 7-Nitro-2-propylthieno[3,2-d]pyrimidin-4(3H)-one (6f). The nitro group was 
inserted in compound 7f (194 mg, 1.0 mmol) according to method B to produce 6f as a 
white solid (156 mg, 65% yield), mp 282-284 °C. 1H NMR (400 MHz; DMSO-d6; TMS) 
δ 12.88 (s, 1H), 9.31 (s, 1H), 2.66 (t, J = 7.5 Hz, 2H), 1.80 – 1.70 (m, 2H), 0.95 (t, J = 
7.3 Hz, 3H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 162.28, 157.95, 149.32, 141.50, 
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138.92, 122.21, 36.66, 20.95, 13.92. HRMS (m/z): [M + H]+ calcd for C9H10N3O3S, 
240.0437; found: 240.0448.  
3.3.15. 7-Nitro-2-(3-nitrophenyl)thieno[3,2-d]pyrimidin-4(3H)-one (6g). Nitro 
group was introduced onto 7g (228 mg, 1.0 mmol) according to method B to obtain 6g 
as a white solid (159 mg, 50% yield), mp >310 °C. 1H NMR (400 MHz; DMSO-d6; 
TMS) δ 13.56 (s, 1H), 9.41 (s, 1H), 9.05 (t, J = 4.1 Hz, 1H), 8.62 (d, J = 8.0 Hz, 1H), 
8.47 (d, J = 8.0 Hz, 1H), 7.90 (t, J = 7.8 Hz, 1H). 13C NMR (100 MHz; DMSO-d6; TMS): 
δ 158.36, 155.04, 148.84, 148.44, 141.70, 139.77, 134.86, 134.14, 130.95, 126.81, 
123.53, 123.47. HRMS (m/z): [M + H]+ calcd for C12H7N4O5S, 319.0132; found: 319.0144.  
3.3.16. 2-Methylthieno[3,2-d]pyrimidin-4(3H)-one (7a). Compound 7a was prepared 
from methyl 3-aminothiophene-2-carboxylate 20 (157 mg, 1.0 mmol)) using method A 
as a white solid (83 mg, 50% yield), mp 235-238 °C [lit. mp 242 °C].44 1H NMR (400 
MHz; DMSO-d6; TMS) δ 12.41 (s, 1H), 8.14 (d, J = 8.2 Hz, 1H), 7.31 (d, J = 8.2 Hz, 
1H), 2.37 (s, 3H). ESI-MS: m/z 167.0 [M + H]+. HPLC flow rate 0.5 mL/min, tR 
(acetonitrile/water 90:10) = 4.2 min, purity 98%. 
3.3.17. 2-Methylfuro[3,2-d]pyrimidin-4(3H)-one (7b).45 Intermediate 24b (50 mg, 0.3 
mmol) was refluxed in a mixture of 4M NaOH aqueous solution (10 mL) and methanol 
(20 mL) for 1 h. The resulting mixture was then neutralized to pH 7 using aqueous 
solution of 1M HCl and extracted with ethyl acetate three times. Organic layers were 
combined, dried over anhydrous MgSO4 and concentrated. The residue was purified 
using flash chromatography by dry loading method to obtain 7b as a white solid (16 
mg, 35% yield), mp 228-231 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.46 (s, 1H), 
8.17 (d, J = 8.2 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 2.34 (s, 3H). 13C NMR (100 MHz; 
DMSO-d6; TMS): δ 155.46, 152.12, 150.32, 148.33, 136.16, 107.89, 20.98. HRMS 
(m/z): [M + H]+ calcd for C7H7N2O2, 151.0502; found: 151.0487.  
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3.3.18. 2-Methylthieno[3,4-d]pyrimidin-4(3H)-one (7c).46 Compound 7c was 
prepared from 24c (55 mg, 0.3 mmol) according the procedure described for the 
preparation of 7b. Compound 7c was obtained as a white solid (20 mg, 40% yield), mp 
200-203 °C [lit. mp 232-233 °C].46 1H NMR (400 MHz; DMSO-d6; TMS) δ 11.62 (s, 
1H), 8.41 (d, J = 3.2 Hz, 1H), 7.63 (d, J = 3.3 Hz, 1H), 2.25 (s, 3H). ESI-MS: m/z 167.0 
[M + H]+. HPLC flow rate 0.5 mL/min, tR (acetonitrile/water 90:10) = 4.4 min, purity 
96%. 
3.3.19. Thieno[3,2-d]pyrimidin-4(3H)-one (7d).47, 48 To a round bottom flask 
containing 20 mL formamide, methyl 3-aminothiophene-2-carboxylate 20 (157 mg, 1.0 
mmol) was added. The reaction mixture was stirred at rt for 6 h. The solution was then 
diluted with 100 mL of ethyl acetate, washed three times with brine and the organic 
layer was dried over MgSO4. Compound 7d was purified using flash chromatography 
by dry loading method as a white solid (99 mg, 65% yield), mp 222-224 °C [lit. mp 
222-223 °C].49 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.51 (s, 1H), 8.19 (d, J = 5.4 
Hz, 1H), 8.16 (s, 1H), 7.41 (d, J = 5.3 Hz, 1H). ESI-MS: m/z 153.0 [M + H]+. HPLC 
flow rate 0.5 mL/min, tR (acetonitrile/water 90:10) = 4.1 min, purity 97%. 
3.3.20. 2-Ethylthieno[3,2-d]pyrimidin-4(3H)-one (7e).44 To synthesize 7e, 
intermediate 23e (170 mg, 0.8 mmol) was treated with 20 mL of 30% ammonium 
hydroxide aqueous solution and stirred for 6 h at rt. Excess ammonia was released at 
low temperature and liquid was removed at high temperature under vacuum to obtain 
7e as a white solid (87 mg, 60% yield). 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.41 
(s, 1H), 8.18 (d, J = 5.2 Hz, 1H), 7.30 (d, J = 2.6 Hz, 1H), 2.65 (t, J = 8.0 Hz, 2H), 0.97 
(t, J = 7.8 Hz, 3H). 
3.3.21. 2-Propylthieno[3,2-d]pyrimidin-4(3H)-one (7f).39 Compound 7f was prepared 
from 23f (182 mg, 0.8 mmol) according to the procedure described for 7e as a white 
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solid (90 mg, 58% yield). 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.39 (s, 1H), 8.14 
(d, J = 5.2 Hz, 1H), 7.34 (d, J = 2.9 Hz, 1H), 2.60 (t, J = 7.6 Hz, 2H), 1.78 – 1.67 (m, 
2H), 0.92 (t, J = 7.4 Hz, 3H). 
3.3.22. 2-Phenylthieno[3,2-d]pyrimidin-4(3H)-one (7g).50 Compound 7g was 
prepared using 23g (209 mg, 0.8 mmol) according to the procedure described for 7e. 
Isolated product was a white solid (51 mg, 28% yield), mp 228-230 °C [lit. 
mp >240 °C].50 1H NMR (400 MHz; D MSO-d6; TMS) δ 12.41 (s, 1H), 8.12 (d, J = 5.42 
Hz, 1H), 7.93 (d, J = 5.4 Hz, 2H,), 7.81 (d, J = 6.7 Hz, 1H), 7.68 – 7.58 (m, 3H). ESI-
MS: m/z 229.0 [M + H]+. HPLC flow rate 1 mL/min, tR (acetonitrile/water 75:25) = 3.3 
min, purity 95%. 
3.3.23. 2,7-Dimethylthieno[3,2-d]pyrimidin-4(3H)-one (7h).51 Compound 7h was 
prepared according to method A from methyl 3-amino-4-methylthiophene-2-
carboxylate 25 (171 mg, 1.0 mmol) as a white solid (77 mg, 43% yield), mp 255-257 °C. 
1H NMR (400 MHz; DMSO-d6; TMS) δ 12.39 (s, 1H), 7.78 (s, 1H), 2.39 (s, 3H), 2.28 
(s, 3H). HRMS (m/z): [M + H]+ calcd for C8H9N2OS, 181.0430; found: 181.0442. 
3.3.24. 7-Methylthieno[3,2-d]pyrimidin-4(3H)-one (7i).43 Compound 7i was prepared 
using methyl 3-amino-4-methylthiophene-2-carboxylate 25 (171 mg, 1.0 mmol) 
according to the procedure described for 7d as a white solid (100 mg, 60% yield), mp 
244-246 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.51 (s, 1H), 8.18 (s, 1H), 7.84 
(s, 1H), 2.32 (s, 3H). ESI-MS: m/z 167.0 [M + H]+. HPLC flow rate 1 mL/min, tR 
(acetonitrile/water 65:35) = 6.2 min, purity 95%. 
3.3.25. (E)-7-Nitro-2-styrylthieno[3,2-d]pyrimidin-4(3H)-one (8a). Compound 8a 
was prepared using 6a (150 mg, 0.7 mmol) and benzaldehyde (0.36 mL, 3.5 mmol) 
according to method C as a brown solid (60 mg, 28% yield), mp >310 °C. 1H NMR 
(400 MHz; DMSO-d6; TMS) δ 13.00 (s, 1H), 9.35 (s, 1H), 7.98 (d, J = 16.0 Hz, 1H), 
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7.69 (d, J = 6.9 Hz, 2H), 7.50 – 7.43 (m, 3H), 7.07 (d, J = 16.1 Hz, 1H). 13C NMR (100 
MHz; DMSO-d6; TMS): δ 157.90, 155.90, 149.42, 141.60, 140.33, 139.33, 135.08, 
130.64, 129.63, 128.33, 122.33, 120.66. HRMS (m/z): [M + H]+ calcd for C14H10N3O3S, 
300.0437; found: 300.0454.  
3.3.26. (E)-2-(2-(Furan-2-yl)vinyl)-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one (8b). 
Compound 8b was prepared using 6a (150 mg, 0.7 mmol) and furan-2-carbaldehyde 
(0.29 mL, 3.5 mmol) according to method C as a dark brown solid (45 mg, 22% yield), 
mp >310 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.99 (s, 1H), 9.34 (s, 1H), 7.90 
(s, 1H), 7.81 (d, J = 15.5 Hz, 1H), 7.02 (d, J = 3.4 Hz, 1H), 6.82 (d, J = 15.5 Hz, 1H), 
6.68 (q, J = 1.3 Hz, 1H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 157.87, 155.77, 
151.27, 149.40, 146.30, 141.44, 139.28, 127.15, 121.92, 117.29, 116.09, 113.37. 
HRMS (m/z): [M + H]+ calcd for C12H8N3O4S, 290.0230; found: 290.0253.  
3.3.27. (E)-7-Nitro-2-(2-(thiophen-2-yl)vinyl)thieno[3,2-d]pyrimidin-4(3H)-one 
(8c). Compound 8c was prepared using 6a (150 mg, 0.7 mmol) and 2-thiophene 
carbaldehyde (0.33 mL, 3.5 mmol) according to method C as a dark brown solid (66 
mg, 31% yield), mp >310 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.90 (s, 1H), 
9.34 (s, 1H), 8.14 (d, J = 15.4 Hz, 1H), 7.74 (d, J = 4.9 Hz, 1H), 7.56 (d, J = 3.3 Hz, 
1H), 7.19 (t, J = 3.7 Hz, 1H), 6.80 (d, J = 15.3 Hz, 1H). 13C NMR (100 MHz; DMSO-
d6; TMS): δ 157.88, 155.71, 149.42, 141.49, 140.17, 139.33, 133.30, 132.21, 129.89, 
129.24, 122.03, 118.94. HRMS (m/z): [M + H]+ calcd for C12H8N3O3S2, 306.0002; found: 
306.0011.  
3.3.28. (E)-4-(2-(7-Nitro-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-
yl)vinyl)benzoic acid (8d). Compound 8d was prepared using 6a (150 mg, 0.7 mmol) 
and 4-formylbenzoic acid (525 mg, 3.5 mmol) according to method C as a dark brown 
solid (58 mg, 24% yield), mp >310 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 13.10 
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(s, 2H), 9.36 (s, 1H), 8.04 – 8.00 (m, 3H), 7.80 (d, J = 8.2 Hz, 2H), 7.18 (d, J = 16.3 
Hz, 1H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 167.27, 157.88, 155.54, 149.30, 
141.58, 139.42, 139.13, 139.00, 132.17, 130.48, 128.40, 122.99, 122.68. HRMS (m/z): 
[M + H]+ calcd for C15H10N3O5S, 344.0336; found: 344.0349.  
3.3.29. (E)-5-(2-(7-Nitro-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-
yl)vinyl)furan-2-carboxylic acid (8e). Compound 8e was prepared using 6a (150 mg, 
0.7 mmol) and 5-formyl-2-furoic acid (490 mg, 3.5 mmol) according to method C as a 
dark brown solid (47 mg, 20% yield), mp >310 °C. 1H NMR (400 MHz; DMSO-d6; 
TMS) δ 13.43 (s, 1H), 13.03 (s, 1H), 9.36 (s, 1H), 7.83 (d, J = 15.8 Hz, 1H), 7.34 (d, J 
= 3.6 Hz, 1H), 7.16 (d, J = 3.6 Hz, 1H), 7.05 (d, J = 15.8 Hz, 1H). 13C NMR (100 MHz; 
DMSO-d6; TMS): δ 159.46, 157.70, 155.13, 153.92, 149.19, 146.31, 141.47, 139.39, 
126.38, 122.53, 120.98, 120.09, 116.79. HRMS (m/z): [M + H]+ calcd for C13H8N3O6S, 
334.0128; found: 334.0149.  
3.3.30. (E)-2-(4-Fluorostyryl)-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one (8f). 
Compound 8f was prepared from 6a (150 mg, 0.7 mmol) and 4-fluorobenzaldehyde 
(0.38 mL, 3.5 mmol) according to method C as a brown solid (44 mg, 20% yield), 
mp >310 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 13.00 (s, 1H), 9.34 (s, 1H), 7.96 
(d, J = 16.0 Hz, 1H), 7.76 (dd, J = 10.2 Hz, 4.2 Hz, 2H), 7.32 (t, J = 8.9 Hz, 2H), 7.02 
(d, J = 16.4 Hz, 1H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 163.50 (d, J = 247.8 Hz), 
157.84, 155.77, 149.33, 141.47, 139.36, 138.97, 131.68 (d, J = 3.0 Hz), 130.52 (d, J = 
8.2 Hz), 122.27, 120.45, 116.58 (d, J = 21.5 Hz). HRMS (m/z): [M + H]+ calcd for 
C14H9FN3O3S, 318.0343; found: 318.0363.  
3.3.31. (E)-2-(2-Fluorostyryl)-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one (8g). 
Compound 8g was prepared using 6a (150 mg, 0.7 mmol) and 2-fluorobenzaldehyde 
(0.38 mL, 3.5 mmol) according to method C as a dark brown solid (82 mg, 37% yield), 
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mp 301-303 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 13.11 (s, 1H), 9.36 (s, 1H), 
8.01 (d, J = 16.0 Hz, 1H), 7.80 (t, J = 3.7 Hz, 1H), 7.52 – 7.48 (m, 1H), 7.37 – 7.31 (m, 
2H), 7.18 (d, J = 16.4 Hz, 1H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 161.03 (d, J = 
249.4 Hz), 157.87, 155.64, 149.30, 141.58, 139.41, 132.53 (d, J = 3.4 Hz), 129.44, 
129.41, 125.68 (d, J = 3.4 Hz), 123.19 (d, J = 6.4 Hz), 122.75, 122.72 (d, J = 27.7 Hz), 
116.73 (d, J = 21.8 Hz). HRMS (m/z): [M + H]+ calcd for C14H9FN3O3S, 318.0343; found: 
318.0367.  
3.3.32. (E)-2-(3-Fluorostyryl)-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one (8h). 
Compound 8h was prepared using 6a (150 mg, 0.7 mmol) and 3-fluorobenzaldehyde 
(0.38 mL, 3.5 mmol) according to method C as a dark brown solid (73 mg, 33% yield), 
mp 304-307 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 13.03 (s, 1H), 9.36 (s, 1H), 
7.96 (d, J = 16.2 Hz, 1H), 7.58 – 7.51 (m, 3H), 7.31 – 7.26 (m, 1H), 7.12 (d, J = 16.2 
Hz, 1H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 162.99 (d, J = 244.1 Hz), 157.85, 
155.59, 149.31, 141.60, 139.35, 138.88, 137.65 (d, J = 8.1 Hz), 131.57 (d, J = 8.3 Hz), 
124.60 (d, J = 2.3 Hz), 122.61, 122.35, 117.27 (d, J = 21.4 Hz), 114.55 (d, J = 21.9 Hz). 
HRMS (m/z): [M + H]+ calcd for C14H9FN3O3S, 318.0343; found: 318.0341. 
3.3.33. (E)-7-Nitro-2-(4-nitrostyryl)thieno[3,2-d]pyrimidin-4(3H)-one (8i). 
Compound 8i was obtained using 6a (150 mg, 0.7 mmol) and 4-nitrobenzaldehyde (529 
mg, 3.5 mmol) according to method C as a dark orange solid (48 mg, 20% yield), 
mp >310 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 13.11 (s, 1H), 9.36 (s, 1H), 8.30 
(d, J = 8.8 Hz, 2H), 8.04 (d, J = 16.0 Hz, 1H), 7.96 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 
16.1 Hz, 1H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 157.80, 155.19, 149.18, 148.22, 
141.60, 141.49, 139.49, 137.67, 129.36, 125.01, 124.70, 123.00. HRMS (m/z): [M + 
H]+ calcd for C14H9N4O5S, 345.0288; found: 345.0333. 
	 30	
3.3.34. (E)-4-(2-(7-Nitro-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-
yl)vinyl)benzonitrile (8j). Compound 8j was prepared from 6a (150 mg, 0.7 mmol) 
and 4-cyanobenzaldehyde (459 mg, 3.5 mmol) according to method C as a dark brown 
solid (70 mg, 31% yield), mp >310 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 13.08 
(s, 1H), 9.36 (s, 1H), 8.00 (d, J = 8.4 Hz, 3H), 7.80 (d, J = 7.5 Hz, 2H), 7.17 (d, J = 15.7 
Hz, 1H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 167.30, 157.99, 155.64, 149.29, 
141.59, 139.38, 139.12, 138.95, 132.25, 130.47, 128.38, 123.09, 122.68. ESI-MS: m/z 
325.0 [M + H]+. HPLC flow rate 1 mL/min, tR (acetonitrile/water 50:50) = 3.0 min, 
purity 95%. 
3.3.35. (E)-2-(4-Chlorostyryl)-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one (8k). 
Compound 8k was prepared using 6a (150 mg, 0.7 mmol) and 4-chlorobenzaldehyde 
(492 mg, 3.5 mmol) according to method C as a dark brown solid (47 mg, 20% yield), 
mp 307-308 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 13.02 (s, 1H), 9.35 (s, 1H), 
7.95 (d, J = 15.9 Hz, 1H), 7.71 (d, J = 8.6 Hz, 2H), 7.54 (d, J = 8.5 Hz, 2H), 7.07 (d, J 
= 16.1 Hz, 1H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 157.94, 155.74, 149.35, 
141.57, 139.36, 138.86, 135.06, 134.04, 130.02, 129.66, 122.48, 121.54. HRMS (m/z): 
[M + H]+ calcd for C14H9ClN3O3S, 334.0048; found: 334.0072.  
3.3.36. (E)-2-(4-Ethynylstyryl)-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one (8l). 
Compound 8l was prepared from 6a (150 mg, 0.7 mmol) and 4-ethynylbenzaldehyde 
(455 mg, 3.5 mmol) according to method C as a dark brown solid (57 mg, 25% yield), 
mp >310 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 13.04 (s, 1H), 9.36 (s, 1H), 7.97 
(d, J = 16.3 Hz, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.57 (d, J = 8.1 Hz, 2H), 7.10 (d, J = 
16.0 Hz, 1H), 4.39 (s, 1H). ). 13C NMR (100 MHz; DMSO-d6; TMS): δ 159.25, 157.89, 
155.89, 149.41, 141.58, 140.31, 139.32, 138.94, 135.08, 130.63, 129.62, 128.32, 
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122.32, 120.65. HRMS (m/z): [M + H]+ calcd for C16H10N3O3S, 324.0437; found: 
324.0463.  
3.3.37. (E)-2-(4-Hydroxystyryl)-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one (8m). 
Compound 8m was prepared using 6a (150 mg, 0.7 mmol) and 4-hydroxybenzaldehyde 
(427 mg, 3.5 mmol) according to method C as a dark brown solid (62 mg, 28% yield), 
mp >310 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.90 (s, 1H), 10.09 (s, 1H), 9.34 
(s, 1H), 7.91 (d, J = 15.7 Hz, 1H), 7.52 (d, J = 8.6 Hz, 2H), 6.87 – 6.82 (m, 3H). 13C 
NMR (100 MHz; DMSO-d6; TMS): δ 160.14, 157.97, 156.46, 149.63, 141.53, 140.66, 
139.25, 130.29, 126.14, 121.64, 116.76, 116.50. HRMS (m/z): [M + H]+ calcd for 
C14H10N3O4S, 316.0387; found: 316.0402.  
3.3.38. (E)-2-(4-Methoxystyryl)-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one (8n). 
Compound 8n was prepared using 6a (150 mg, 0.7 mmol) and 4-methoxybenzaldehyde 
(0.43 mL, 3.5 mmol) according to method C as a dark brown solid (81 mg, 35% yield), 
mp 294-297 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 12.92 (s, 1H), 9.34 (s, 1H), 
7.94 (d, J = 15.5 Hz, 1H), 7.64 (d, J = 9.0 Hz, 2H), 7.03 (d, J = 8.2 Hz, 2H), 6.92 (d, J 
=15.5 Hz, 1H), 3.82 (s, 3H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 161.41, 157.94, 
156.28, 149.53, 141.53, 140.15, 139.21, 130.05, 127.68, 121.84, 117.93, 115.09, 55.82. 
HRMS (m/z): [M + H]+ calcd for C15H12N3O4S, 330.0543; found: 330.0573.  
3.3.39. 3-Benzyl-2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one (9a). 
Compound 9a was prepared from the reaction of 6a (106 mg, 0.5 mmol) and benzyl 
bromide (0.11 mL, 0.9 mmol) according to method D as a white solid (72 mg, 48% 
yield), mp 220-221 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.36 (s, 1H), 7.38 – 
7.28 (m, 3H), 7.22 (d, J = 7.3 Hz, 2H), 5.43 (s, 2H), 2.56 (s, 3H). 13C NMR (100 MHz; 
DMSO-d6; TMS): δ 160.06, 157.81, 147.49, 141.18, 139.77, 136.07, 129.31, 128.00, 
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126.89, 121.98, 47.03, 23.64. HRMS (m/z): [M + H]+ calcd for C14H12N3O3S, 302.0594; 
found: 302.0616.  
3.3.40. 2-Methyl-7-nitro-3-phenethylthieno[3,2-d]pyrimidin-4(3H)-one (9b). 
Compound 9b was obtained from the reaction of 6a (106 mg, 0.5 mmol) and (2-
bromoethyl)benzene (0.12 mL, 0.9 mmol) according to method D as a white solid (66 
mg, 42% yield), mp 227-229 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.33 (s, 1H), 
7.35 – 7.24 (m, 5H), 4.28 (t, J = 7.8 Hz, 2H), 2.99 (t, J = 7.6 Hz, 2H), 2.56 (s, 3H). 13C 
NMR (100 MHz; DMSO-d6; TMS): δ 159.82, 157.35, 147.31, 141.11, 139.52, 138.45, 
129.30, 129.10, 127.19, 121.90, 46.37, 33.78, 23.37. HRMS (m/z): [M + H]+ calcd for 
C15H14N3O3S, 316.0750; found: 316.0766.  
3.3.41. 2-Methyl-7-nitro-3-(3-phenylpropyl)thieno[3,2-d]pyrimidin-4(3H)-one 
(9c). Compound 9c was obtained by reacting 6a (106 mg, 0.5 mmol) with 1-bromo-3-
phenylpropane (0.14 mL, 0.9 mmol) according to method D as a white solid (69 mg, 
42% yield), mp 207-209 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.30 (s, 1H), 7.31 
– 7.26 (m, 4H), 7.20 – 7.16 (m, 1H), 4.08 (t, J = 7.9 Hz, 2H), 2.71 (t, J = 7.6 Hz, 2H), 
2.62 (s, 3H), 2.21 – 1.94 (m, 2H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 159.74, 
157.41, 147.28, 141.33, 141.07, 139.35, 128.78, 128.72, 126.41, 121.86, 44.45, 32.77, 
29.31, 23.32. HRMS (m/z): [M + H]+ calcd for C16H16N3O3S, 330.0907; found: 330.0927.  
3.3.42. 2-Methyl-7-nitro-3-(4-nitrobenzyl)thieno[3,2-d]pyrimidin-4(3H)-one (9d). 
Compound 9d was prepared by reacting 6a (106 mg, 0.5 mmol) with 4-nitrobenzyl 
bromide (194 mg, 0.9 mmol) according to method D as a dark orange solid (104 mg, 
60% yield), mp 218-220 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.38 (s, 1H), 8.21 
(d, J = 8.7 Hz, 2H), 7.52 (d, J = 8.8 Hz, 2H), 5.55 (s, 2H), 2.56 (s, 3H). 13C NMR (100 
MHz; DMSO-d6; TMS): δ 159.94, 157.75, 147.57, 147.37, 143.91, 141.21, 139.86, 
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128.20, 124.39, 121.97, 46.96, 23.70. HRMS (m/z): [M + H]+ calcd for C14H11N4O5S, 
347.0445; found: 347.0456.  
3.3.43. 2-Methyl-7-nitro-3-(2-nitrobenzyl)thieno[3,2-d]pyrimidin-4(3H)-one (9e). 
Compound 9e was obtained from the reaction of 6a (106 mg, 0.5 mmol) and 2-
nitrobenzyl bromide (194 mg, 0.9 mmol) according to method D as a white solid (95 
mg, 55% yield), mp 190-192 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.38 (s, 1H), 
8.23 (d, J = 8.2 Hz, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.61 (t, J = 8.0 Hz, 1H), 7.08 (d, J = 
7.7 Hz, 1H), 5.71 (s, 2H), 2.54 (s, 3H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 160.09, 
157.66, 147.87, 147.68, 141.23, 139.80, 135.17, 131.21, 129.31, 127.09, 125.98, 
121.93, 45.54, 23.52. HRMS (m/z): [M + H]+ calcd for C14H11N4O5S, 347.0445; found: 
347.0468.  
3.3.44. 2-Methyl-7-nitro-3-(3-nitrobenzyl)thieno[3,2-d]pyrimidin-4(3H)-one (9f). 
Compound 9f was prepared using 6a (106 mg, 0.5 mmol) and 3-nitrobenzyl bromide 
(194 mg, 0.9 mmol) according to method D as a white solid (83 mg, 48% yield), mp 
194-197 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.37 (s, 1H), 8.18 – 8.16 (m, 2H), 
7.70 – 7.63 (m, 2H), 5.55 (s, 2H), 2.58 (s, 3H). 13C NMR (100 MHz; DMSO-d6; TMS): 
δ 159.98, 157.88, 148.51, 147.56, 141.20, 139.85, 138.39, 133.62, 130.87, 123.05, 
122.24, 122.00, 46.71, 23.78. HRMS (m/z): [M + H]+ calcd for C14H11N4O5S, 347.0445; 
found: 347.0462.  
3.3.45. 4-((2-Methyl-7-nitro-4-oxothieno[3,2-d]pyrimidin-3(4H)-
yl)methyl)benzonitrile (9g). Compound 9g was prepared from the reaction of 6a (106 
mg, 0.5 mmol) and 4-cyanobenzyl bromide (176 mg, 0.9 mmol) according to method 
D as a white solid (72 mg, 44% yield), mp 198-200 °C. 1H NMR (400 MHz; DMSO-d6; 
TMS) δ 9.37 (s, 1H), 7.84 (d, J = 7.2 Hz, 2H), 7.44 (d, J = 7.5 Hz, 2H), 5.50 (s, 2H), 
2.54 (s, 3H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 159.91, 157.74, 147.52, 141.82, 
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141.14, 139.86, 133.19, 127.88, 121.97, 119.09, 110.80, 47.05, 23.67. HRMS (m/z): 
[M + H]+ calcd for C15H11N4O3S, 327.0546; found: 327.0562.  
3.3.46. 3-(4-Methoxybenzyl)-2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one 
(9h). Compound 6a (106 mg, 0.5 mmol) was reacted with 4-methoxybenzyl bromide 
(0.13 mL, 0.9 mmol) according to method D to obtain 9h as a white solid (80 mg, 48% 
yield), mp 189-192 °C.  1H NMR (400 MHz; DMSO-d6; TMS) δ 9.35 (s, 1H), 7.19 (d, 
J = 8.7 Hz, 2H), 6.91 (d, J = 8.7 Hz, 2H), 5.34 (s, 2H), 3.73 (s, 3H), 2.58 (s, 3H). 13C 
NMR (100 MHz; DMSO-d6; TMS): δ 160.07, 159.09, 157.85, 147.41, 141.11, 139.78, 
128.53, 127.85, 122.00, 114.66, 55.55, 46.53, 23.62. HRMS (m/z): [M + H]+ calcd for 
C15H14N3O4S, 332.0700; found: 332.0714.  
3.3.47. Ethyl 2-(2-methyl-7-nitro-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl)acetate 
(10a). Compound 10a was prepared by reacting 6a (211 mg, 1.0 mmol) with ethyl 
bromoacetate (0.2 mL, 1.8 mmol) according to method D as a white solid (134 mg, 45% 
yield), mp 145-147 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.36 (s, 1H), 5.00 (s, 
2H), 4.20 (q, J = 7.3 Hz, 2H), 2.61 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz; 
DMSO-d6; TMS): δ 167.96, 159.86, 157.22, 147.55, 141.22, 140.01, 121.31, 62.14, 
46.06, 23.05, 14.44. HRMS (m/z): [M + H]+ calcd for C11H12N3O5S, 298.0492; found: 
298.0498. 
3.3.48. tert-Butyl 2-(2-methyl-7-nitro-4-oxothieno[3,2-d]pyrimidin-3(4H)-
yl)acetate (10b). Compound 6a (211 mg, 1.0 mmol) was reacted with tert-butyl 2-
chloroacetate (0.26 mL, 1.8 mmol) to obtain 10b as a white solid (195 mg, 60% yield), 
mp 190-193 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.36 (s, 1H), 4.91 (s, 2H), 2.58 
(s, 3H), 1.44 (s, 9H). 13C NMR (100 MHz; DMSO-d6; TMS): δ167.02, 159.81, 157.21, 
147.51, 141.20, 139.98, 121.34, 83.08, 46.50, 28.06, 23.46. HRMS (m/z): [M + H]+ 
calcd for C13H16N3O5S, 326.0805; found: 326.0804. 
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3.3.49. 2-(2-Methyl-7-nitro-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl)acetic acid 
(10c). Compound 10a (100 mg, 0.3 mmol) was hydrolyzed to obtain 10c (52 mg, 65% 
yield) as a white solid by following procedure described for preparation of 27, mp 225-
228 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 13.52 (s, 1H), 9.35 (s, 1H), 4.92 (s, 
2H), 2.60 (s, 3H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 169.31, 159.93, 157.24, 
147.51, 141.19, 139.88, 121.38, 45.96, 23.48. HRMS (m/z): [M + H]+ calcd for 
C9H8N3O5S, 270.0179; found: 270.0173. 
3.3.50. 2-(2-Methyl-7-nitro-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl)-N-
phenylacetamide (10d).52 A mixture of compound 10c (269 mg, 1.0 mmol), EDC (211 
mg, 1.1 mmol), HBTU (417 mg, 1.1 mmol) and triethylamine (0.28 mL, 2.0 mmol) in 
dichloromethane was stirred for 30 min, then aniline (0.15 mL, 1.5 mmol) was added. 
Upon complete conversion of starting material, the reaction mixture was diluted with 
water and subsequently extracted with ethyl acetate. Combined organic layers were 
dried over MgSO4 and evaporated. Crude product was purified using dry loading 
method and dichloromethane/methanol mobile phase on flash chromatography to 
obtain 10d as a light yellow solid (121 mg, 35% yield), mp 260-262 °C. 1H NMR (400 
MHz; DMSO-d6; TMS) δ 10.51 (s, 1H), 9.36 (s, 1H), 7.58 (d, J = 7.4 Hz, 2H), 7.33 (t, 
J = 7.4 Hz, 2H), 7.08 (t, J = 4.3 Hz, 1H), 5.04 (s, 2H), 2.63 (s, 3H). 13C NMR (100 MHz; 
DMSO-d6; TMS): δ 165.22, 160.51, 157.42, 147.57, 141.20, 139.88, 138.95, 129.38, 
124.18, 121.41, 119.59, 47.55, 23.72. HRMS (m/z): [M + H]+ calcd for C15H13N4O4S, 
345.0652; found: 345.0626. 
3.3.51. 2-Methyl-3-(2-morpholino-2-oxoethyl)-7-nitrothieno[3,2-d]pyrimidin-
4(3H)-one (10e). Compound 10e was prepared as per the procedure described for 10d 
using compound 10c (269 mg, 1.0 mmol) and morpholine (0.13 mL, 1.5 mmol) as 
starting materials. Purified product was obtained as a white solid (112 mg, 33% yield), 
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mp 239-241 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.35 (s, 1H), 5.15 (s, 2H), 3.68 
(t, J = 3.3 Hz, 2H), 3.60 (t, J = 4.6 Hz, 4H), 3.47 (t, J = 4.1 Hz, 2H), 2.53 (s, 3H). 13C 
NMR (100 MHz; DMSO-d6; TMS): δ 164.81, 160.42, 157.29, 147.52, 141.20, 139.69, 
121.39, 66.51, 45.49, 45.30, 23.50. HRMS (m/z): [M + H]+ calcd for C13H15N4O5S, 
339.0758; found: 339.0739. 
3.3.52. 2-Methyl-3-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-7-nitrothieno[3,2-
d]pyrimidin-4(3H)-one (10f). Compound 10f was prepared as per the procedure 
described for 10d, using compound 10c (269 mg, 1.0 mmol) and N-methyl piperazine 
(0.17 mL, 1.5 mmol) as starting materials. Purified product was obtained as a white 
solid (141 mg, 40% yield), mp 140-143 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 
9.34 (s, 1H), 5.14 (s, 2H), 3.57 (t, J = 4.7 Hz, 2H), 3.48 (t, J = 5.0 Hz, 2H), 2.52 (s, 3H), 
2.41 (t, J = 4.7 Hz, 2H), 2.30 (t, J = 4.7 Hz, 2H), 2.22 (s, 3H). HRMS (m/z): [M + H]+ 
calcd for C14H18N5O4S, 352.1074; found: 352.1074. 
3.3.53. 4-Chloro-2-methyl-7-nitrothieno[3,2-d]pyrimidine (11a).53 Compound 6a 
(211 mg, 1.0 mmol) was added into a round bottom flask containing phosphorus 
oxychloride (20 mL, 215 mmol). Reaction mixture was stirred under reflux for 18 h. 
Once starting material was fully converted, the solution was transferred portion wise 
into ice water. The mixture was neutralized with aqueous solution of NaHCO3 and 
extracted 3 times with ethyl acetate. Organic layers were combined, dried over 
anhydrous MgSO4 and evaporated. Resulting crude product was purified by flash 
chromatography (dichloromethane/methanol 93:3) to obtain a pale yellow solid (92 mg, 
40% yield), mp 164-165 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.69 (s, 1H), 2.81 
(s, 3H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 156.32, 152.18, 147.02, 140.67, 
140.63, 135.54, 115.89. HRMS (m/z): [M + H]+ calcd for C7H5ClN3O2S, 229.9786; found: 
229.9765. 
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3.3.54. 2-Methyl-7-nitro-N-phenylthieno[3,2-d]pyrimidin-4-amine (11b).53 
Compound 11a (50 mg, 0.2 mmol) and aniline (0.09 mL, 1.0 mmol) were added into a 
microwave tube. The mixture was kept in a single cavity microwave initiator, and the 
reaction was carried out at 150 °C for 50 min. The reaction mass was diluted with a 
mixture of ethyl acetate/water. Organic layer was separated, dried over MgSO4, and 
evaporated. Resulting crude product was purified by flash chromatography 
(dichloromethane/methanol 99:1) to obtain 11b as a white solid (20 mg, 35% yield), 
mp 202-205 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 10.01 (s, 1H), 9.36 (s, 1H), 
7.78 (d, J = 7.7 Hz, 2H), 7.41 (t, J = 7.7 Hz, 2H), 7.17 (t, J = 7.7 Hz, 1H), 2.57 (s, 3H). 
13C NMR (100 MHz; DMSO-d6; TMS): δ 165.72, 155.54, 151.79, 141.17, 139.10, 
138.91, 129.19, 124.76, 123.11, 113.89, 26.31. HRMS (m/z): [M + H]+ calcd for 
C13H11N4O2S, 287.0597; found: 287.0621. 
3.3.55. 4-(2-Methyl-7-nitrothieno[3,2-d]pyrimidin-4-yl)morpholine (11c). 
Compound 11c was prepared as per the procedure described for 11b, using 11a (50 mg, 
0.2 mmol) and morpholine (0.09 mL, 1.0 mmol) as starting materials. Target compound 
was isolated as a pale yellow solid (25 mg, 45% yield), mp 182-185 °C. 1H NMR (400 
MHz; DMSO-d6; TMS) δ 9.40 (s, 1H), 3.93 (t, J = 5.1 Hz, 4H), 3.76 (t, J = 5.1 Hz, 4H), 
2.53 (s, 3H). HRMS (m/z): [M + H]+ calcd for C11H13N4O3S, 281.0703; found: 281.0724. 
3.3.56. (E)-3-Benzyl-2-(4-fluorostyryl)-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one 
(12a). Reaction of 9a (100 mg, 0.3 mmol) and 4-fluorobenzaldehyde (0.16 mL, 1.5 
mmol) was carried out according to method C to obtain 12a as a brown solid (27 mg, 
22% yield), mp 192-195 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.40 (s, 1H), 7.93 
(d, J = 15.1 Hz, 1H), 7.78 (q, J = 3.4 Hz, 2H), 7.40 – 7.22 (m, 8H), 5.70 (s, 2H). HRMS 
(m/z): [M + H]+ calcd for C21H15FN3O3S, 408.0813; found: 408.0815. 
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3.3.57. (E)-4-Chloro-2-(4-fluorostyryl)-7-nitrothieno[3,2-d]pyrimidine (12b). 
Compound 8f (100 mg, 0.3 mmol) was reacted with phosphorous oxychloride (15 mL, 
161 mmol) to afford 12b using procedure described for the preparation of 11a as a 
yellow solid (72 mg, 72% yield), mp 256-258 °C. 1H NMR (400 MHz; DMSO-d6; TMS) 
δ 9.69 (s, 1H), 8.06 (d, J = 16.1 Hz, 1H), 7.95 – 7.91 (m, 2H), 7.42 (d, J = 16.0 Hz, 1H), 
7.28 (t, J = 8.9 Hz, 2H). 13C NMR (100 MHz; DMSO-d6; TMS): δ 162.34 (d, J = 247.8 
Hz), 162.08, 153.90, 151.96, 143.35, 140.01, 138.23, 131.15 (d, J = 2.9 Hz), 129.81 (d, 
J = 8.6 Hz), 126.55, 125.14, 115.33 (d, J = 21.7 Hz). HRMS (m/z): [M + H]+ calcd for 
C14H8ClFN3O2S, 336.0004; found: 335.9991. 
3.3.58. (E)-4-(2-(4-fluorostyryl)-7-nitrothieno[3,2-d]pyrimidin-4-yl)morpholine 
(12c). Compound 12b (67 mg, 0.2 mmol) and morpholine (0.09 mL, 1.0 mmol) were 
reacted according to the procedure described for 11b to afford 12c as a white solid (25 
mg, 32% yield), mp 245-248 °C. 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.43 (s, 1H), 
7.93 (d, J = 16.3 Hz, 1H), 7.82 (dd, J = 8.3 Hz, 3.2 Hz, 2H), 7.25 (t, J = 8.3 Hz, 2H), 
7.15 (d, J = 7.8 Hz, 1H), 4.02 (t, J = 8.9 Hz, 4H), 3.81 (t, J = 3.8 Hz, 4H). 13C NMR 
(100 MHz; DMSO-d6; TMS): δ 162.98 (d, J = 247.3 Hz), 161.71, 157.63, 152.85, 
141.60, 137.98, 136.81, 132.77 (d, J = 3.3 Hz), 130.28 (d, J = 8.2 Hz), 128.08, 116.25 
(d, J = 21.6 Hz), 113.05, 66.33, 46.30. HRMS (m/z): [M + H]+ calcd for C18H16FN4O3S, 
387.0922; found: 387.0938. 
3.3.59. 2-Methyl-8-nitro-4H-benzo[d][1,3]oxazin-4-one (16). Intermediate 16 was 
prepared using commercially available methyl 2-amino-3-nitrobenzoate 13 (196 mg, 
1.0 mmol) and acetic anhydride according to method A as an orange solid (180 mg, 87% 
yield). 1H NMR (400 MHz; DMSO-d6; TMS) δ 8.12 (d, J = 7.9 Hz, 1H), 8.08 (d, J = 
8.0 Hz, 1H), 7.49 (t, J = 7.9 Hz, 1H), 2.05 (s, 3H). 
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3.3.60. 2-Methyl-4H-pyrido[2,3-d][1,3]oxazin-4-one (17).54 Intermediate 17 was 
prepared using commercially available methyl 2-aminonicotinate 14 (152 mg, 1.0 
mmol) and acetic anhydride according to method A as a white solid (105 mg, 65% 
yield). 1H NMR (400 MHz; DMSO-d6; TMS) δ 8.22 (dd, J = 4.9 Hz, 1.7 Hz, 1H), 8.15 
(dd, J = 7.8 Hz, 1.8 Hz, 1H), 6,70 (dd, J = 7.7 Hz, 4.9 Hz, 1H), 3.83 (s, 3H). 
3.3.61. 8-Fluoro-2-methyl-4H-benzo[d][1,3]oxazin-4-one (18). Intermediate 18 was 
prepared using commercially available methyl 2-amino-3-fluorobenzoate 15 (169 mg, 
1.0 mmol) and acetic anhydride according to method A as a white solid (143 mg, 80% 
yield). 1H NMR (400 MHz; DMSO-d6; TMS) δ 7.93 (d, J = 7.7 Hz, 1H), 7.81 (d, J = 
8.0 Hz, 1H), 7.58 (t, J = 7.9 Hz, 1H), 2.43 (s, 3H). 
3.3.62. Methyl 3-acetamidothiophene-2-carboxylate (22a). Intermediate 22a was 
prepared using commercially available methyl 3-aminothiophene-2-carboxylate 19 
(157 mg, 1.0 mmol) and acetic anhydride (20 mL) according to method A as a white 
solid (167 mg, 84% yield). 1H NMR (400 MHz; CDCl3; TMS) δ 9.99 (s, 1H), 7.93 (d, 
J = 5.4 Hz, 1H), 7.89 (d, J = 5.4 Hz, 1H), 3.84 (s, 3H), 2.17 (s, 3H). 
3.3.63. Methyl 3-acetamidofuran-2-carboxylate (22b).55 Intermediate 22b was 
prepared using commercially available methyl 3-aminofuran-2-carboxylate 20 (141 mg, 
1.0 mmol) and acetic anhydride (20 mL) according to method A as a white solid (119 
mg, 65% yield). 1H NMR (400 MHz; CDCl3; TMS) δ 12.66 (s, 1H), 7.85 (s, 1H), 6.82 
(s, 1H), 2.64 (s, 3H), 2.33 (s, 3H). 
3.3.64. Methyl 4-acetamidothiophene-3-carboxylate (22c). Intermediate 22c was 
prepared using commercially available methyl 4-aminothiophene-3-carboxylate 21 
(157 mg, 1.0 mmol) and acetic anhydride (20 mL) according to method A as a white 
solid (165 mg, 83% yield). 1H NMR (400 MHz; DMSO-d6; TMS) δ 9.83 (s, 1H), 8.35 
(d, J = 3.5 Hz, 1H), 7.90 (d, J = 3.6 Hz, 1H), 3.85 (s, 3H), 2.13 (s, 3H). 
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3.3.65. Methyl 3-propionamidothiophene-2-carboxylate (22e).56 Methyl 3-
aminothiophene-2-carboxylate 19 (157 mg, 1.0 mmol) was stirred with triethylamine 
(0.21 mL, 1.5 mmol) and propionyl bromide (0.11 mL, 1.2 mmol) in dichloromethane 
at room temperature for 4 h. The mixture was then neutralized with 1 molar aqueous 
HCl solution and extracted with dichloromethane three times. Combined organic layers 
were dried over anhydrous MgSO4 and concentrated under vacuum. Product was 
isolated as a white solid (171 mg, 80% yield). 1H NMR (400 MHz; DMSO-d6; TMS) δ 
10.02 (s, 1H), 7.97 (d, J = 5.4 Hz, 1H), 7.90 (d, J = 5.4 Hz, 1H), 3.84 (s, 3H), 2.46 (t, J 
= 7.5 Hz, 2H), 1.11 (t, J = 7.5 Hz, 3H). 
3.3.66. Methyl 3-butyramidothiophene-2-carboxylate (22f). Intermediate 22f was 
prepared using methyl 3-aminothiophene-2-carboxylate 19 (157 mg, 1.0 mmol) and 
butanoyl bromide (0.12 mL, 1.2 mmol) as starting materials following procedure 
described for the preparation of 22e. Isolated product was white solid (193 mg, 85% 
yield). 1H NMR (400 MHz; DMSO-d6; TMS) δ 10.11 (s, 1H), 8.03 (d, J = 5.3 Hz, 1H), 
7.89 (d, J = 5.3 Hz, 1H), 3.83 (s, 3H), 2.76 (t, J = 7.4 Hz, 2H), 1.51 – 1.37 (m, 2H), 
0.91 (t, J = 7.4 Hz, 3H). 
3.3.67. Methyl 3-benzamidothiophene-2-carboxylate (22g). Intermediate 22g was 
prepared using methyl 3-aminothiophene-2-carboxylate 19 (157 mg, 1.0 mmol) and 
benzoyl bromide (0.14 mL, 1.2 mmol) as starting materials by procedure described for 
the preparation of 22e. Isolated product was white solid (214 mg, 82% yield). 1H NMR 
(400 MHz; DMSO-d6; TMS) δ 11.02 (s, 1H), 8.12 (d, J = 5.3 Hz, 1H), 8.00 (d, J = 5.3 
Hz, 1H,), 7.96 (d, J = 7.1 Hz, 2H), 7.71 – 7.61 (m, 3H), 3.89 (s, 3H). 
3.3.68. Methyl 3-acetamido-4-methylthiophene-2-carboxylate (22h). Intermediate 
22h was prepared using commercially available methyl 3-amino-4-methylthiophene-2-
carboxylate 24 (171 mg, 1.0 mmol) and acetic anhydride as starting materials according 
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to method A as a white solid (160 mg, 75% yield). 1H NMR (400 MHz; CDCl3; TMS) 
δ 9.62 (s, 1H), 7.51 (s, 1H), 3.75 (s, 3H), 2.03 - 2.02 (m, 6H). 
3.3.69. 3-Acetamidofuran-2-carboxamide (23b).57 Intermediate 23b was prepared 
using 22b (168 mg, 1.0 mmol) and ammonium hydroxide aqueous solution (30 mL) 
according to method A as a white solid (103 mg, 62% yield). 1H NMR (400 MHz; 
DMSO-d6; TMS) δ 9.66 (s, 1H), 7.77 (s, 1H), 7.70 (d, J = 1.7 Hz, 1H), 7.55 (s, 1H), 
7.22 (d, J = 1.7 Hz, 1H), 2.10 (s, 3H). 
3.3.70. 4-Acetamidothiophene-3-carboxamide (23c).46 Intermediate 23c was prepared 
using 22c (199 mg, 1.0 mmol) and ammonium hydroxide aqueous solution (30 mL) 
according to method A as a white solid (74 mg, 40% yield). 1H NMR (400 MHz; 
DMSO-d6; TMS) δ 11.00 (s, 1H), 8.27 (d, J = 3.4 Hz, 1H), 8.14 (s, 1H), 7.87 (d, J = 3.3 
Hz, 1H), 7.61 (s, 1H), 2.08 (s, 3H). 
3.4. Minimum Inhibitory Concentrations (MICs) of Thienopyrimidinone 
Analogues against C. difficile Strains 
Following the guidelines defined by the Clinical and Laboratory Standards Institute 
(CLSI),58 Clostridium difficile strains were grown anaerobically on brain heart infusion 
supplemented (BHIS) agar plates (Brain heart infusion, BD, supplemented with yeast 
extract, Vitamin K1 and Hemin, Sigma) at 37 °C for 48 h. Afterwards, a bacterial 
suspension of ~105 CFU/mL was prepared in BHIS broth and seeded in 96-well plates 
containing serial dilutions of the compounds and controls. Plates were then incubated 
anaerobically at 37 °C for 48 h. Reported MICs are the minimum concentration of each 
compound at which inhibition of the bacterial growth could be visually observed.59 The 
MBC of the most potent compound, 8f, was determined by subculturing 8f-inhibited 
bacteria on a drug-free BHIS agar plates and incubated anaerobically at 37 °C for 24 h. 
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Reported MBC is the concentration at which 99.9% of the initial bacterial count was 
eradicated.60, 61  
3.5. Time-kill assay of 8f against C. difficile 
An 18-20 h culture of C. difficile ATCC BAA 1870 was diluted 1:50 in fresh BHIS 
broth to achieve a starting concentration of 106 CFU/mL. The bacterial suspension was 
mixed with 8 X MIC of 8f, vancomycin, fidaxomicin or DMSO in triplicates. Bacterial 
concentration was measured at the indicated time points by serially diluting samples 
from each bacterial suspension followed by culturing, in duplicates on BHIS agar plates. 
CFU were counted after anaerobic incubation for 24 h at 37 °C.62  
3.6. In Vitro Antimicrobial Evaluation of Thienopyrimidinone Analogues against 
Normal Microflora 
With slight modification, CLSI and previous reports were followed in order to 
determine the MICs of the most active compounds against human microflora.63, 64 
Bacteria were first grown for 48 hours at 37 °C, anaerobically using BHIS agar for 
Bifidobacterium and in 5% CO2 using MRS agar plate for Lactobacillus. Approximately 
a 105 CFU/mL suspension was prepared (in BHIS broth for Bifidobacterium or in MRS 
broth for Lactobacillus) for each strain and seeded in 96-well plates. Compounds were 
added at the required concentrations in the 96-well plates and incubated as mentioned 
for each species for 48 hours at 37 °C before recording the MIC values. 
For Escherichia coli and Enterobacter cloacae, the activity of the compounds was 
tested in accordance with the CLSI.63 Briefly, bacteria were grown on tryptic soy agar 
(TSA) plates for 16-20 h at 37 °C. A bacterial suspension was prepared in phosphate 
buffered saline (PBS), matched to the turbidity of a 0.5 McFarland standard solution 
and diluted in tryptic soy broth (TSB) to achieve a bacterial concentration of ~ 105 
CFU/mL. The final bacterial suspension was incubated in 96-well plates with serial 
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dilutions of the compounds and the controls for 16-20 h at 37 °C. MICs were defined 
as the lowest concentration of each agent that inhibited the bacterial growth.65, 66  
3.7. In Vitro Cytotoxicity Analysis of Thienopyrimidinone Analogues 
The most potent compounds were selected for further testing for their cytotoxicity 
against three different cell lines; human colon colorectal adenocarcinoma (Caco-2), 
human ileocecal adenocarcinoma (HRT-18) and African green monkey kidney cells 
(Vero) as described previously.67, 68 Briefly, cells were grown in T75 flasks at 37 °C in 
5% CO2 atmosphere till they reached ~90% confluency using the growth media 
recommended by the supplier. Cells were transferred to cell culture-treated 96-well 
plates, incubated at 37 °C in 5% CO2 and allowed to reach confluency. Next, the growth 
media were replaced with fresh ones containing the indicated concentrations of the 
compounds or DMSO (as a negative control) in triplicates and incubated at 37 °C in 5% 
CO2 for 2 h. After incubation, media were removed, and the cells were washed before 
the addition of 20% MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium). Added MTS was incubated with the cells for 
additional 4 h at 37 °C in 5% CO2, then the absorbance for each well was recorded as 
an optical density at 490 nm. Data is presented as percentage cell viability as compared 
to the DMSO treated cells. 
3.8. Determination of the Aqueous Solubility of Thienopyrimidinone Analogues 
Solution at a concentration of 1 mg/mL was obtained by dissolving interested 
compound in methanol. The stock solution was passed through a 0.45-micron nylon 
membrane filter. Samples at different concentrations (1 μg/mL, 5 μg/mL, 50 μg/mL, 
and 100 μg/mL) were prepared and loaded onto HPLC. Isocratic mobile phase 
(acetonitrile/water 50:50) was used and a flow rate as 1.0 mL/min. Standard curve was 
achieved by plotting AUC (area under the curve) versus concentration at 254 nm. To 
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prepare saturated solution, 3 mg of target compound was added into an Eppendorf tube 
containing 3 mL PBS solution. The mixture was agitated for 24 h at 25 °C and 
centrifuged for 3 min at 16000 rpm. A mixture of 300 μL of supernatant and 300 μL 
acetonitrile was prepared. Absorbance was measured on HPLC, and solubility was 
calculated from absorbance, standard curve and dilution factor. 
3.9. Assessment of the Stability of Thienopyrimidinone Analogues in Simulated 
Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF) 
Stability of target compounds in SGF (pH = 1.6) and SIF (pH = 6.0) was evaluated 
following reported procedure with modification. Stock solutions at concentration of 50 
μg/mL were prepared with methanol. Mixture of 200 μL of stock solution and 800 μL 
SGF/SIF was stirred vigorously and incubated at 37 °C. After 4 h and 8 h incubation, 
samples were loaded onto HPLC and eluted using isocratic mobile phase 
(acetonitrile/water 50:50) at a flow rate of 1.0 mL/min. The remaining percentage at 
each injection time point was calculated as AUC (after incubation)/AUC (before 
incubation) at λ 254 nm.69  
3.10. In Silico PAINS Analysis 
All the synthesized target compounds were subjected to PAINS filters by using a 
KNIME (v3.74, KNIME GmbH, Konstanz, Germany) workflow.70 Molecular formula 
strings of target compounds were manually input into the workflow, and the output file 
for the run indicated no PAINS were found. 
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Chapter IV. Results and Discussion 
4.1. Chemistry 
To pursue more potent C. difficile inhibitor by exploring chemical space around 
thieno[3,2-d]pyrimidin-4(3H)-one scaffold, target compounds were obtained according 
to synthetic routes described in schemes 1- 6. 
4.1.1. Synthesis of Fused Pyrimidinone Derivatives 
Fused pyrimidinone derivatives were synthesized starting from amino and methyl ester 
substituted aromatic/heteroaromatic intermediates (Scheme 1). Acetylation of 
commercially available chemicals 13-15 and 19-21 was performed using acetic 
anhydride, and subsequent treatment of intermediates with ammonium hydroxide to 
obtain compounds 2-4 and 7a.34 Hydrogenation of the nitro group of 2 yielded 5.42 The 
reaction conditions used for the preparation of 7b and 7c required an alternate strategy 
due to varying reactivity of starting materials. As illustrated, intermediates 23b and 23c 
were prepared according to the procedure used for the synthesis of compound 2 and 
heated in a mixture of NaOH, water and methanol to obtain the cyclized compounds 7b 
and 7c.45 The nitro group was introduced on 7a-7c by treating with fuming nitric acid 
and concentrated sulfuric acid mixture to obtain nitro derivatives 6a-6c.71   
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Scheme 1. Reagents and conditions: (a) acetic anhydride, 13 (for 16), 14 (for 17), 15 
(for 18), 19 (for 22a), 20 (for 22b), 21 (for 22c), rt, 12-24 h, 65-85%; (b) 30% NH4OH, 
16 (for 2), 17 (for 3), 18 (for 4), 22a (for 7a), 22b (for 23b), 22c (for 23c), rt, 6-8 h, 62-
70%; (c) H2/Pd/C, MeOH, 50 psi, rt, 8 h, 70%; (d) Aq. NaOH, MeOH, 23b (for 7b), 
23c (for 7c), reflux, 4-6 h, 35-40%; (e) HNO3, conc. H2SO4, 0 °C - rt, 4-12 h, 40-82%.  
4.1.2. Synthesis of Thienopyrimidinone Derivatives 
To investigate the role of C2-methyl group, 7d-7g with C2-H, -ethyl, -propyl, and -
phenyl substituents were prepared from 19 and 22e-22g, respectively.47, 72 The nitrated 
derivatives 6d-6f were prepared from 7d-7f by following the same method used for the 
preparation of 6a.71 Target compound 6g was obtained from nitration of 7g wherein two 
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nitro groups (C7 of the bicyclic scaffold and meta-position of the C2-phenyl substituent) 
were introduced in the same reaction. To analyze the role of C7-nitro group, compounds 
with C7-methyl group (7h and 7i) were synthesized from commercially available 24 
over two-steps for 7h and one-step for 7i (Scheme 2). 
 
Scheme 2. Reagents and conditions: (a) formamide, rt, 6-8 h, 60-65%; (b) HNO3, conc. 
H2SO4, 7e (for 6e), 7f (for 6f), 7g (for 6g), 0 °C - rt, 6-8 h, 50-70%. (c) triethyl amine, 
DCM, propionyl bromide (for 22e), butanoyl bromide (for 22f), benzoyl chloride (for 
22g), rt, 4-8 h, 80-85%; (d) 30% NH4OH, 22e (for 7e), 22f (for 7f), 22g (for 7g), 22h 
(for 7h), rt, 6-8 h, 28-60%; (e) acetic anhydride, rt, 14 h, 75%.  
4.1.3. Synthesis of C2-Styryl Derivatives 
To pursue more potent compounds, lead 6a was condensed with (un)substituted 
aromatic/heteroaromatic aldehydes using microwave conditions to obtain C2-styryl 
derivatives 8a-8n (Scheme 3). 73, 74 
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Scheme 3. (a) benzaldehyde (for 8a), furfural (for 8b), 2-thiophenecarboxalehyde (for 
8c), 4-formylbenzoic acid (for 8d), 5-formyl-2-furoic acid (for 8e), 4-
fluorobenzaldehyde (for 8f), 2-fluorobenzaldehyde (for 8g), 3-fluorobenzaldehyde (for 
8h), 4-nitrobenzaldehyde (for 8i), 4-cyanobenzaldehyde (for 8j), 4-chlorobenzaldehyde 
(for 8k), 4-ethynylbenzaldehyde (for 8l), 4-hydroxylbenzaldehyde (for 8m), 4-
methoxybenzaldehyde (for 8n), AcOH, MW, 180 °C, 5-6 h, 20-37%. 
4.1.4. Synthesis of N3-Substituted Derivatives 
A wide range of substituents were installed at N3-position of 6a as shown in Scheme 4. 
For example, 9a-9h were prepared by reacting 6a with various (un)substituted 
phenylalkyl halides in the presence of potassium carbonate in DMF.39 To prepare 
analogues with N3-ester (11a and 11b), -carboxylic acid (11c), and -amide (11d-11f) 
substituents, 6a was subjected to alkylation using respective halides in the presence of 
potassium carbonate and DMF to obtain 11a and 11b.39 The ester 11a was hydrolyzed 
in the presence of lithium hydroxide to obtain 11c, and the resulting carboxylic acid 
was coupled with aromatic/aliphatic amines to yield  11d-11f.52  
	 49	
 
Scheme 4. (a) benzyl bromide (for 9a), (2-bromoethyl)benzene (for 9b), 1-bromo-3-
phenylpropane (for 9c), 4-nitrobenzyl bromide (for 9d), 2-nitrobenzyl bromide (for 9e), 
3-nitrobenzyl bromide (for 9f), 4-cyanobenzyl bromide, (for 9g), 4-methoxybenzyl 
bromide (for 9h), ethyl bromoacetate (for 10a), tert-butyl 2-chloroacetate (for 10b), 
K2CO3, DMF, rt, 8-12 h, 42-60%; (b) LiOH, THF, H2O, rt, 8-10 h, 65-87%; (c) aniline 
(for 10d), morpholine (for 10e), N-methyl piperazine (for 10f), EDC, HBTU, 
triethylamine, DCM, rt, 6h, 33-40%. 
4.1.5. Synthesis of C4-Substituted Analogues 
As depicted in Scheme 5, compound 11a was prepared from the reaction of 6a with 
phosphorus oxychloride. The C4-chloro group was then nucleophilically displaced by 




Scheme 5. (a) phosphorus oxychloride, reflux, 18 h, 40%, (b) aniline (for 11b), 
morpholine (for 11c), DMF, MW, 150 °C, 50-70 min, 35-45%. 
4.1.6. Synthesis of Disubstituted Analogues of Thienopyrimidinone Core 
Target compound 12a with C2- and N3-disubstitution was prepared from the reaction 
of 9a and 4-fluorobenzaldehyde. The 2,4-disubstituted compound 12b was obtained by 
treating 8f with phosphorus oxychloride, which upon nucleophilic substitution by 
morpholine led to 12c as shown in Scheme 6. 
 
Scheme 6. (a) 4-fluorobenzaldehyde, AcOH, MW, 180 °C, 4 h, 22%, (b) phosphorus 
oxychloride, reflux, 18 h, 72%; (c) morpholine, DMF, MW, 150 °C, 1 h, 32%. 
4.2. Elucidation of Regioisomers from Nitration Reaction 
Variety of techniques, including X-ray crystallography, 1-D (1H and 13C) and 2-D 
(HSQC and HMBC) NMR analyses, were employed to determine the regioselectivity 
of products obtained from the nitration reaction. We hypothesized that the position of 
the nitro group in representative compound 6a would be at C7 instead of C6. This 
hypothesis was tested initially based on determination of the single X-ray crystal 
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structure of 6a-derived analogue 10b, and supported by 1H and 13C NMR chemical shifts 
analyses. Unambiguous assignment of regioisomer 11b was accomplished by solving 
its single X-ray crystal structure (Figure 5).  
 
Figure 5. Crystal structure of compound 10b (CCDC 1884213). 
The C6-thiophene proton chemical shift of 6a is 9.30 ppm and 10b is 9.36 ppm (Figure 
6 and Figure 7), and the thiophene C6 chemical shift of 6a and 10b are 138.99 ppm 
and 139.98 ppm (Figure 8 and Figure 9), respectively. These similar chemical shifts 
provide evidence for identical regioisomerism within compounds 6a and 10b. There is 
no distinct HMBC correlation present to differentiate the nitro group’s position on the 
furan ring of compound 6b (Figure 10), but reactivity of the starting material 7b is 
similar to the sulfur-isostere analogue 7a, from which compound 6a was derived. 
Therefore, we believe that the nitro group is at 7-position in 6b as well. HMBC spectra 





Figure 6. 1H NMR spectra of 6a. 
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Figure 7. 1H NMR spectra of 10b. 
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Figure 8. 13C NMR spectra of 6a. 
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Figure 9. 13C NMR spectra of 10b. 
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Figure 10. HMBC spectrum of 6b. 
 
Figure 11. HMBC spectrum of 7b. 
Both HSQC and HMBC experiments were performed to investigate correlations 
between carbons and protons within compound 7c, which was the starting material for 
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the nitration reaction to generate 6c. The correlation between individual carbon atom 
and the proton attached to it was evidenced by the HSQC spectrum of 7c (Figure 12). 
Additional HMBC analysis of 7c shows four HMBC correlations for the hydrogen at 
5-position, and three HMBC correlations for the hydrogen at 7-position as expected 
(Figure 13). Subsequent HMBC spectrum of compound 6c shows four HMBC 
correlations for a single thiophene proton (Figure 14). These observations lead to the 
conclusion that the nitration reaction afforded the 7-nitro analogue as the exclusive 
regioisomer.  
 
Figure 12. HSQC spectrum of 7c. 
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Figure 13. HMBC spectrum of 7c. 
 
Figure 14. HMBC spectrum of 6c. 
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For analogues 6d – 6g, which are structurally analogous to 6a, we observed that the 
thiophene proton (9.31 – 9.41 ppm) and the carbon atom (138.89 – 139.21 ppm) with 
proton attached, have very similar chemical shift values compared to compound 6a (1H 
9.30 ppm, 13C 138.99 ppm) indicating the presence of nitro group at 7-position (Table 
3). 
Table 3. 1H and 13C Chemical shift of compound 6a, 6d – 6g, and 10b 
Compound Structure 
















































4.3. Structure-Activity Relationship 
An in vitro antibacterial screening protocol was designed to identify compounds with 
potent inhibitory activity toward C. difficile, and minimal effect on normal human 
microflora and mammalian cells. To achieve this goal, we tested target compounds 
against two pathogenic strains of C. difficile (ATCC BAA 1870 and ATCC 43255) as 
shown in Tables 1-5. MIC values (µM and µg/mL) are used to describe antibacterial 
activities of the compounds and used for the interpretation of SAR data. An initial SAR 
study was focused on elucidation of the role of nitro substituent on hit-to-lead scaffolds 
6a-6c toward C. difficile inhibition as shown in Table 1. Des-nitro analogues of 6a-6c 
gave 7a (MIC >770/385 µM), 7b (MIC >852/852 µM), and 7c (MIC = 192/768 µM) 
with a substantial loss of anti-C. difficile potency. Other des-nitro derivatives such as 
7d (MIC = 420/840 µM), 7g (MIC >560/>560 µM), 7h (MIC >710/>710 µM), and 7i 
(MIC >770/>770 µM) were also manifested with a loss of potency. These results 
allowed us to conclude the essential role of a nitro substituent at the C7-position. Next, 
we decided to elucidate the contribution of a C2-methyl group on anti-C. difficile 
potency (Table 3). Toward this goal, we prepared and tested C2-desmethyl (6d, MIC = 
20/10 µM), C2-ethyl (6e, MIC = 35/35 µM), C2-propyl (6f, MIC = 67/67 µM) and C2-
meta-nitrophenyl (6g, MIC = 50/50 µM) analogues exhibiting potency comparable to 
that of 6a. Therefore, we hypothesized that further extensions at the C2-position may 
















335 (64) 335 (64) 
2 
 
312 (64) 156 (32) 
3 
 
>794 (>128) >794 (>128) 
4 
 
>718 (>128) >718 (>128) 
5 
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192 (32) 768 (128) 
7d 
 
420 (64) 840 (128) 
7g 
 
>560 (>128) >560 (>128) 
7h 
 
>710 (>128) >710 (>128) 
7i 
 
>770 (>128) >770 (>128) 
Vancomycin - 0.7 (1) 0.3 (0.5) 
Metronidazole - 0.7 (0.125) 1.5 (0.25) 
Fidaxomicin - 0.1 (0.0625) 0.1 (0.0625) 
Table 5 shows the MICs of C2-styryl analogues. The C2-styryl derivative 8a 
yielded a promising MIC of 13/52 µM. Considering the favorable result, we replaced 
the phenyl ring with isosteres such as furan-2-yl (8b, MIC = 27/27 µM) and thiophen-
2-yl (8c, MIC = 13/13 µM) which suggested the tolerance for these isosteric 
replacements. Next, we prepared carboxy substituted derivatives of 8a and 8b leading 
to 8d (MIC = 46/184 µM) and 8e (MIC >384/>384 µM) with a considerable loss of 
potency. This loss of potency may be attributed to unfavorable interactions with the 
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target and/or poor permeability. On the contrary, 4-fluorophenyl analogue (8f, MIC = 
3/6 µM) showed excellent potency. A fluoro-scan was conducted to identify the most 
favorable position for a fluoro group, which led to 2-fluoro (8g, MIC = 6/12 µM) and 
3-fluoro (8h, MIC = 13/13 µM) analogues. Since 4-fluoro analogue yielded the potent 
MIC value, we explored substitutions of different electron-withdrawing/-donating 
groups at the 4-position. While 4-nitro analogue (8i, MIC = 24/12 µM) gave 
comparable activity, the 4-cyano analogue (8j, MIC >197/>197 µM) proved 
detrimental. The 4-chloro analogue (8k, MIC = 6/6 µM) being a classical isostere of 4-
fluoro group retained potency similar to that observed for the 4-fluoro analogue. 
Retention of potency by 4-acetylene derivative (8l, MIC = 6/12 µM) indicated a 
tolerance for the conformationally rigid acetylene group. Similar to the electron-
withdrawing groups, electron-donating groups also showed favorable potency as 
exemplified by 4-hydroxy (8m, MIC = 26/13 µM) and 4-methoxy (8n, MIC = 12/12 
µM) analogues. 
Table 5. MIC of Compounds with C2 Substitutions 
Compound Structure 
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Vancomycin - 0.7 (1) 0.3 (0.5) 






The next SAR included investigation of various N3-substituents in lead 6a as 
shown in Table 6. At the onset, we inserted N3-substituents such as benzyl (9a, MIC = 
7/56 µM), phenylethyl (9b, MIC = 13/13 µM) and phenylpropyl (9c, MIC = 12/12 µM) 
	 67	
to investigate the influence of varying linker length and obtained comparable potency 
to that observed for 6a. Based on these analogues, it may be suggested that the binding 
pocket of N3-substituents is located further from the N3-position. Based on the 
favorable MIC values and straightforward derivatization, we chose benzyl analogue 9a 
for further SAR study. Scanning of the nitro group on the benzyl moiety at different 
positions produced 4-nitro (9d, MIC = 6/12 µM), 2-nitro (9e, MIC = 23/23 µM) and 3-
nitro (9f, MIC = 23/23 µM) analogues. Considering favorable contribution of 4-
substituents, we prepared 4-cyano analogue (9g, MIC = 25/50 µM), which showed 4-
fold reduced potency. The electron-donating 4-methoxy analogue (9h, MIC = 24/24 
µM) also suffered a loss of activity compared to 9d. These findings prompted us to 
investigate untapped chemical space around 6a, which led to N3-ethoxycarbonyl 
methylene analogue (10a, MIC = 54/54 µM), N3-tert-butyloxycarbonyl methylene 
analogue (10b, MIC = 49/98 µM), and methylene carboxylic acid (10c, 
MIC >475/>475 µM). This data suggested the tolerance for an ester group at N3-
position. The detrimental effect of a carboxyl group in 10c may be due to poor 
permeability through C. difficile cell membrane and/or unfavorable interaction with the 
target, which is consistent with the activity loss observed for the other carboxylic acid 
analogues 8d, and 8e. Thus, we decided to convert unfavorable carboxyl group to an 
amide by coupling it with an aniline, morpholine, and N-methylpiperazine, respectively, 
to produce 10d (MIC = 46/23 µM), 10e (MIC = 47/94 µM), and 11f (MIC = 91/91 µM) 
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49 (16) 98 (32) 
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>475 (>128) >475 (>128) 
10d 
 
46 (16) 23 (8) 
10e 
 
47 (16) 94 (32) 
10f 
 
91 (32) 91 (32) 
Vancomycin - 0.7 (1) 0.3 (0.5) 
Metronidazole - 0.7 (0.125) 1. 5 (0.25) 
Fidaxomicin - 0.1 (0.0625) 0.1 (0.0625) 
Our next SAR involved expansion of a chemical space around C4-position of 6a, 
which led to synthesis of C4-chloro derivative (11a, MIC = 17/34 µM) as shown in 
Table 7. We noticed that 11a featured a significant change in the scaffold structure 
(transforming sp3-hybridized N3 to sp2-hybridized N3) with increased planarity, and still 
exhibited comparable activity to that of 6a. We took advantage of the ease of 
nucleophilically displacing the C4-chloro with aniline and morpholine to obtain 11b 
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(MIC = 28/14 µM) and (11c, MIC = 14/14 µM) with essentially retention of activity as 
that of 11a. 










17 (4) 34 (8) 
11b 
 
28 (8) 14 (4) 
11c 
 
14 (4) 14 (4) 
Vancomycin - 0.7 (1) 0.3 (0.5) 
Metronidazole - 0.7 (0.125) 1.5 (0.25) 
Fidaxomicin - 0.1 (0.0625) 0.1 (0.0625) 
The SAR data gathered so far indicated the favorable contribution of C2-arylidene, 
N3-benzyl and C4-chloro derivatives for C. difficile growth inhibition. Next, we 
decided to combine these structural features into a single molecule to evaluate whether 















157 (64) 157 (64) 
12b 
 
95 (32) 95 (32) 
12c 
 
166 (64) 166 (64) 
Vancomycin - 0.7 (1) 0.3 (0.5) 
Metronidazole - 0.7 (0.125) 1. 5 (0.25) 
Fidaxomicin - 0.1 (0.0625) 0.1 (0.0625) 
 This has led to the synthesis and testing of C2-, N3-disusbtituted analogue (12a, MIC 
= 157/157 µM) with substantial loss of activity. The C2-, C4-disubstituted analogues 
12b (MIC = 95/95 µM) and 12c (MIC = 166/166 µM) were also proved detrimental. 
This data suggests that the disubstitutions oppose each other’s productive binding 
within respective pockets of the target. Overall summary of the SAR findings is 
depicted in Figure 15. 
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Figure 15. SAR summary of the thienopyrimidinone series of anti-C. difficille agents.  
4.4. Killing kinetics of 8f against C. difficile 
After exploration of the chemical space around lead compound 6a, we sought to 
investigate the killing kinetics of the most potent compound in the series, 8f. The 
minimum bactericidal concentration (MBC) of compound 8f was 6 µM, which is two-
fold higher than its MIC. We concluded that compound 8f is bactericidal, based on the 
fact that the MBC value is lower than 3 X MIC value. To confirm the bactericidal 
activity of compound 8f, we performed a time-kill assay and compared killing kinetics 
of 8f to the standard anti-clostridial drugs, vancomycin and fidaxomicin, at 8 X MIC. 
Interestingly, compound 8f completely eradicated the bacteria in 6 h after incubation as 




Figure 16. Time-kill assay of compound 8f against C. difficile ATCC BAA 1870. 
4.5. Selectivity of representative compounds against C. difficile over normal cells 
We next investigated the toxicity of representative compounds (6a, 8f, 8g, 8k, 9a, 9c, 
9d and 11c) against human and animal cells. As presented in Figure 17, the cytotoxicity 
of the most potent compounds was tested against three cell lines; human colon 
colorectal adenocarcinoma (Caco-2 cells), human ileocecal adenocarcinoma (HRT-18 
cells) and African green monkey kidney cells (Vero cells). All tested compounds 
showed no toxicity against the tested cell lines at >256 μM. 
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Figure 17. In vitro cytotoxicity evaluation of the most potent compounds against 3 
different cell lines; human colon colorectal adenocarcinoma (Caco-2), human ileocecal 
adenocarcinoma (HRT-18) and African green monkey kidney cells (Vero). 
4.6. Selectivity of representative compounds against C. difficile over gut flora 
Since the killing of beneficial gut microflora leads to a significant growth of 
opportunistic pathogens such as C. difficile and subsequent colonization and recurrence 
of CDI, it is important to determine whether representative set of compounds (6a, 8f, 
8g, 8k, 9a, 9c, 9d and 11c) are selective toward C. difficile while sparing normal gut 
microflora. These compounds did not show any activity against human normal gut 
bacteria at >425 µM, including Lactobacillus, Bifidobacterium, E. coli, and 
Enterobacter cloacae (Table 9). On the contrary MICs of positive controls 





Table 9. Activity of Selected Compounds against Human Normal Floraa 
 
MIC (µM) 



















































































































































NT NT NT <1 
NT = Not tested 
4.7. Aqueous solubility and SGF/SIF stability of representative compounds 
Aqueous solubility plays an important role in determining the suitability of 
thienopyrimidinone derivatives for targeting the site of action i.e., intestine and also to 
facilitate preclinical to clinical transition, therefore we determined the solubility of 
representative potent compounds in PBS buffer (pH 7.3 to 7.5). Compound 6a 
showed >500 µg/mL solubility in PBS buffer whereas compounds 8f, 9c, 9d, and 11c 
exhibited lower solubility ranging from 10 to 20 µg/mL. Stability of these compounds 
in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) was also evaluated 
at two time points (Table 10). We observed that SGF stability followed the order of 
9d>6a>8f>9c>11c, whereas SIF stability was in the order of 9d>6a>11c>8f>9c.  
Table 10. Aqueous Solubility in PBS Buffer (pH 7.3 – 7.5) and Stability in SGF 









in SGF 4 h 
Percentage 
remaining 
in SGF 8 h 
Percentage 
remaining 
in SIF 4 h 
Percentage 
remaining 
in SIF 8 h 
6a >500 90% 90% 91% 76% 
8f 14.79 50% 48% 60% 51% 
9c 10.76 45% <10% <10% <10% 
9d 12.73 >95% >95% >95% 90% 
11c 18.69 <10% <10% 79% 80% 
a Aqueous solubility was determined in PBS buffer at pH 7.3 – 7.5. 
metronidazole: 10 mg/mL in water;75 
vancomycin hydrochloride: 17.6 mg/mL in water;76 
fidaxomicin: 18 µg/mL at pH 7. 
4.8. In Silico PAINS Analysis.  
All the synthesized target compounds were subjected to PAINS filters by using a 
KNIME (v3.74, KNIME GmbH, Konstanz, Germany) workflow.70 Molecular formula 
strings of target compounds were manually input into the workflow, and the output file 





The SAR data gathered during hit identification and hit-to-lead exploratory medicinal 
chemistry revealed key pharmacophore features of thienopyrimidinone series that 
contributed to the potency against clinical strains of C. difficile. These observations 
included: a) the nitrophenyl portion of the screening hit 2 can be replaced with isosteric 
nitrothienyl and nitrofuranyl to enhance potency in ligand-efficient fashion (e.g., 2 vs 
6a-6c), b) the C2-methyl substitution does not significantly influence potency (e.g., 6a 
vs 6d-6f), c) the presence of an electron-withdrawing regiospecific nitro group on a 
bicyclic scaffold is indispensable to the potency of these compounds (e.g., 1 vs 2, 7a vs 
6a, 7b vs 6b, and 7c vs 6c), d) the C2-methyl can be extended to an aryl/heteroaryl 
ethenyl moiety without significant loss of potency (e.g., 6a vs 8a-8c, 8f-8i and 8k-8m), 
e) the 3-NH of thienopyrimidinone scaffold can be substituted with various arylalkyl 
moieties, aliphatic esters or aliphatic amides (e.g., 6a vs 9a, 9d-9h, 10a, 10b and 10d-
10f) with retention of potency, f) the C4 carbonyl oxygen can be replaced with chloro 
and aromatic/aliphatic amines with retention of activity (e.g., 6a vs 11a-11c), g) either 
C2-, N3- or C2-, C4-disubstitutions on pyrimidine ring of 6a proved detrimental (e.g., 
6a vs 12a-12c), and h) compounds (e.g., 8d, 8e, and 11c) with the carboxylic acid 
substituent showed detrimental activities. The most promising compound (8f) from this 
series exhibited excellent profile: i) potent and rapid killing against C. difficile strains, 
ii) excellent selectivity over human normal flora, iii) low cytotoxicity against 
mammalian cells, iv) increased GI stability, and v) desirable aqueous solubility. Unlike 
synthetically intractable and architecturally complex macrocyclic antibiotics, 
vancomycin (MW = 1449 Da) and fidaxomicin (MW = 1058 Da) that are difficult to 
structurally optimize, the current series of small MW thienopyrimidinones offer 
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significant scope for further medicinal chemistry optimization to explore SAR, and 
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